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– i –Abstract
Abstract
In the developed societies cardiovascular disease (CVD) is the leading cause of death. 
Angiotensin II (Ang II) contributes to the development of CVD by acting as a potent 
vasoconstrictor, but also as growth factor and by promoting endothelial dysfunction. In 
vascular smooth muscle cells (VSMC), Ang II promotes cell growth (hypertrophy). It 
was recently shown that the red wine polyphenol resveratrol (RV) inhibits Ang II-induced 
hypertrophy by interfering with the PI3K/Akt pathway. This was suggested to occur by 
the activation of the phosphatase SH2-domain containing phosphatase 2 (Shp2), a redox-
sensitive molecule. The current work is based on the hypothesis that RV can restore Shp2 
activity by interfering with reactive oxygen species (ROS) produced downstream of the 
activated epidermal growth factor receptor (EGF-R) that is transactivated in VSMC in 
response to Ang II. Inhibition of ROS production will prevent oxidation and thus inhibition 
of Shp2. Specifi c aims of this thesis were to examine a) whether RV acts as antioxidant 
when inhibiting Akt phosphorylation in Ang II- and EGF-activated VSMC, b) to identify 
the source of ROS responsible for Akt activation downstream of the EGF-R, c) to verify 
the role of Shp2 as a RV target in VSMC and to determine whether RV affects Shp2 by a 
redox-sensitive mechanism. 
In this study we indeed show an antioxidative effect of RV, as it inhibits intracellular ROS 
in Ang II-activated VSMC and also basal ROS levels. When testing the dependence of 
Ang II- and EGF-induced phosphorylation/activation of major signalling molecules such as 
Akt, p38 and ERK1/2 on ROS, we found that Ang II-induced phosphorylation of Akt and 
p38 is dependent on ROS produced by Nox1, whereas EGF-stimulated phosphorylation 
of these kinases was shown to occur redox-independent. Using non-redox active derivates 
of RV in this setting underlined that antioxidative properties of RV are not necessary for 
the inhibition of phosphorylation of Akt. Approaching the role of Shp2 in the molecular 
mechanism of RV in VSMC we were unable to detect changes in the oxidation status of 
Shp2 but revealed differences in phosphorylation status of Shp2 and PI3K recruitment to 
Shp2 upon Ang II or EGF treatment, suggesting a distinct regulation of Shp2 upon Ang II 
or EGF stimulation. This study indicates that the antioxidant activity of RV is not required 
for the strong Akt inhibitory/antihypertrophic activity of RV in Ang II-activated VSMC. 
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Zusammenfassung
Kardiovaskuläre Erkrankungen sind die häufi gste Todesursache in der westlichen Welt. 
Angiotensin II (Ang II) begünstigt die Entstehung dieser Erkrankungen durch seine Funktion 
als Vasokonstriktor, Wachstumsfaktor und durch Förderung der endothelialen Dysfunktion. 
In glatten Gefäßmuskelzellen führt Ang II zu Zellwachstum (Hypertrophie). Es wurde 
bereits gezeigt, dass das im Rotwein vorhandene Polyphenol Resveratrol (RV) die Ang 
II- induzierte Hypertrophie durch Inaktivierung des PI3K/Akt Signalweges hemmt. Ein 
möglicher Mechanismus dafür wäre die Aktivierung der redoxsensitiven Phosphatase Shp2. 
Die Hypothese, die dieser Arbeit zugrunde liegt, besagt, dass RV Shp2 vor Inaktivierung 
schützt, indem es freie Sauerstoffradikalen reduziert, die nach der Ang II-Stimulation und 
EGF-R Transaktivierung entstehen. Eine Reduzierung dieser Sauerstoffradikale würde die 
Shp2 Aktivität erhalten, da Shp2 nicht durch Oxidation inaktiviert würde. Die detaillierten 
Ziele dieser Arbeit waren: a) zu untersuchen, ob RV die Phosphorylierung von Akt durch 
antioxidative Wirkung hemmt, b) die Quelle der produzierten Sauerstoffradikale zu 
bestimmen, die zur Akt Aktivierung unterhalb des EGF-R beitragen und c) zu klären, ob 
Shp2 das Zielmolekül von RV ist. In Zuge der Arbeit konnten wir einen antioxidativen 
Effekt von RV in unseren Zellen nachweisen, da es in der Lage war, Ang II- induzierte 
intrazelluläre Sauerstoffradikale und das basale Sauerstoffradikallevel zu reduzieren. 
Bei der Überprüfung der Redox-Abhängigkeit von Ang II- u nd EGF- induzierter 
Phosphorylierung und Aktivierung von Akt, p38 und ERK1/2 fanden wir, dass die Ang II 
vermittelte Stimulierung von Akt und p38 Nox1 abhängig ist. Die Phosphorylierung der 
Kinasen nach EGF Stimulation war redox-unabhängig. Mit Hilfe von nicht redoxaktiven 
RV-Derivaten konnten wir ebenfalls zeigen, dass RV nicht als Radikalfänger agiert, wenn es 
die Phosphorylierung von Akt hemmt. Wir konnten weiters keine Oxidierung von Shp2 in 
unseren Zellen feststellen, allerdings fanden wir Unterschiede in der Shp2 Phosphorylierung 
und der Rekrutierung von PI3K zu Shp2 nach Ang II- oder EGF- Aktivierung der Zellen. 
Dies deutet auf eine unterschiedliche Regulation von Shp2 durch Ang II oder EGF hin. 
Diese Studie zeigt, dass zur Hemmung der Ang II verursachten Akt Phosphorylierung und 
Hypertrophie in glatten Gefäßmuskelzellen die antioxidativen Eigenschaften von RV nicht 
notwendig sind.
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A B C D
B Introduction
1. Atherosclerosis
1.1. Pathogenesis of atherosclerosis
Responsible for about 50 % of all deaths in the developed societies, cardiovascular disease 
(CVD) is the leading mortal disease worldwide. Atherosclerosis commonly results from 
the combination of an unhealthy environment, genetic susceptibility and increased lifespan 
in our society.1, 2 In the beginning of atherosclerosis there is chronic injury to endothelial 
cells (EC) through shear stress, hypertension or other stimuli. Due to increased endothelial 
permeability low-density lipoproteins (LDL) as well as platelets and blood monocytes 
cross the vessel wall and accumulate in the intima. LDL are then modifi ed via oxidation to 
produce oxLDL. This initiates the development of early lesions, consisting of subendothelial 
accumulations of cholesterol-enriched macrophages (“foam cells”) generated by uptake of 
oxLDL (Fig 1A). Then the lesion is advancing to “fatty streaks” by enrichment of lipid-rich 
necrotic debris and VSMC, which are recruited from the media into the intima by growth 
factors or proliferate in the intima directly, secreting large amounts of extracellular-matrix 
components. By recruiting more monocytes and leukocytes to the atherosclerotic lesions 
a chronic infl ammation is perpetuated via secretion of chemokines, cytokines and reactive 
oxygen species (ROS). This again favours the uptake of oxidized LDL in macrophages, 
release of pro-infl ammatory cytokines and recruitment of infl ammatory cells (Fig. 1B). The 
Figure 1: Initiation and progression of atherosclerosis
The fi rst step in the development of atherosclerosis is the formation of a fatty streak (A), which 
can further lead to an intermediate lesion (B); then development of a lesion that is vulnerable 
to rupture can follow (C) and in the end an advanced obstructive lesion can narrow the vessel 
(D). Figure from Rader D.J. et al.8
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originating plaque contains a central lipid core consisting of cholesterol, separated from 
the arterial lumen by a fi brous cap which is produced by VSMC (Fig. 1C). Upon rupture 
of the plaque thrombogenic material is exposed in the lumen leading to a thrombus or by 
continued growth of the plaque the lumen is narrowed.1-4 (Fig.1D)
1.2. Role of vascular smooth muscle cells (VSMC)
Situated in the media of a healthy blood vessel the VSMC usually remain in a quiescent 
state being mainly responsible for vasoconstriction and -dilation. As a consequence of 
injury, which also leads to increased exposure to cytokines and growth factors, VSMC 
change their phenotype into a proliferative one, migrate into the intima and form a so called 
neointimal layer. By excretion of pro-infl ammatory mediators and vascular cell adhesion 
molecules they contribute to infl ammation. Synthesis of matrix molecules by VSMC leads 
to a retention of lipoproteins and VSMC also produce a fi rm fi brous cap which promotes 
plaque formation and consequently intimal thickening.2,5-7 Proliferating and hypertrophic 
VSMC play a dominant role in the development of atherosclerosis. When cultivated 
they also change their phenotype to a proliferative and ECM disposing one which makes 
subcultured VSMC a suitable model for cells found in the neointima8. 
2. Resveratrol 
2.1. Source and history
The polyphenol resveratrol (3,5,4´-trihydroxy-trans-stilbene; RV) (Fig. 2) is a phytoalexin 
which is synthesized in spermatophytes in response to injury, UV irradiation and fungal 
attack.9 It has been found in about 70 plants like grapes, mulberries and peanuts, and was 
fi rst isolated from roots of white hellebore (Veratrum grandifl orum O.Loes) in 19409. 
Positive effects of RV on health were initially claimed in 1963, when it was identifi ed as the 
active constituent of Polygonum cuspidatum (Ko-jo-kon), a traditional Asian medicine10. 
RV became famous after it was discovered in red wine, postulating that it can explain 
some of the cardioprotective effects of red wine11. The phenomenon, known as the “French 
Paradox”, describes the inverse correlation between red wine consumption and incidence of 
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Figure 2: Structure of RV
RV possesses a trans-isomeric form, a stilbenic skeleton 
and three phenol groups.
cardiovascular disease shown in epidemiological studies. In France the incidence of heart 
infarction is about 40 % lower than in the rest of Europe, although the diet is traditionally 
rich in saturated fat.12. 
2.2. Health promoting effects of resveratrol
2.2.1. Vasoprotection
RV can prevent platelet aggregation in vitro13 and was also reported to block increasing 
platelet aggregation in vivo14, further it can reduce atherosclerotic areas and the size of 
generated thrombi15 by modulating COX1 over COX2 activity16. A vasorelaxant activity of 
RV was found in isolated arteries and rat aortic rings17, 18, mediated by multiple pathways 
such as stimulating Ca2+- activated K+ channels and enhancing endothelial nitric oxide 
synthase (eNOS) as well as inducible nitric oxide synthase (iNOS)19. Also low-density 
lipoprotein (LDL) particles can be protected from oxidation by RV as it can chelate copper 
or scavenges free radicals20, 21.
2.2.2. Antioxidant activity
It was shown that phenolic compounds in red wine such as RV have antioxidative activity 
and can therefore prevent LDL oxidation22. Intracellular and extracellular ROS can be 
signifi cantly inhibited at a concentration of 1-100 μM RV. Reason for this effect is that 
RV can scavenge free radicals23,24 and in VSMC it was also shown to enhance endogenous 
antioxidants such as catalase15,25 and to elevate glutathione, a cellular antioxidant, by 
infl uencing its viability and oxidation23. In addition, RV is able to increase endogenous 
antioxidants and phase 2 enzymes in cardiomyocytes which leads to an enhanced cellular 
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defence mechanism against oxidative injuries26. The hydroxyl groups of RV seem to be 
important for the antioxidant activity and the 4´position was determined as the most important 
one for this effect, whereas the 3- and 5- OH groups were shown to act in a synergistic way. 
Also the trans-isomery and the double bond in the stilbenic skeleton play a crucial role for 
the antioxidant effects of RV in cells.27 Recent studies revealed that RV derivatives with 
additional hydroxyl groups like piceatannol (PCA; 3,5,3´,4´-tetrahydroxy-trans-stilbene) 
that is produced by a cytochrome P450 catalyzed hydroxylation of RV show an enhanced 
anti-radical activity.28 In contrast deletion of the hydroxyl group at the 4´position of RV 
reduced its antioxidant activity.27, 29
2.2.3. Cancer
Augmented research on RV and cancer began after the fi rst report of a benefi cial outcome 
when treating skin tumours topically with RV. Several publications described the inhibitory 
potential of RV on initiation and growth of tumours in a wide variety of rodent cancer 
models.9, 30 RV can impair cancer development in various ways: by inhibiting carcinogen 
activation, induction of carcinogen detoxifying enzymes, modulating cell survival and 
apoptosis, inhibition of angiogenesis and blocking metastasis.9, 31, 32 Currently, Phase I 
clinical trials are underway including one study where RV is given to patients with colon 
cancer and another for safety and the pharmacokinetic profi le of repeated administration of 
RV.9, 31
2.2.4. Aging and sirtuins
Sirtuins or Sir (silent information regulator) 2-like proteins belong to a conserved family 
of NAD+-dependent histone (class III histone)/protein deacetylases (HDAC). They can 
deacetylate chromatin and therefore create transcriptionally silent chromatin33. Sirt 1-7 
were also found to be able to deacetylate non-histone proteins such as p53, Forkhead 
box-O transcription factors (FOXO) and α-tubulin at lysine residues. Deacetylation by 
HDAC of these residues are often a prerequisite for subsequent ubiquitination and protein 
degradation.33, 34 Lately RV was found to extend the lifespan of S.cerevisiae, Caenorhabditis 
elegans and Drosophila melanogaster.35, 36, and also of a species of short-lived fi sh 37. The 
proteins which are thought to be responsible for this phenomenon are the yeast Sir2. Also 
its mammalian homolog SIRT1 is linked to extending life, as knock out mice lacking SIRT1 
had a reduced lifespan38. Furthermore, RV was found in an initial in vitro screen as the most 
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potent of 18 inducers of SIRT1 deacetylase activity35. These effects of RV on SIRT1 were 
not reproducible when not using a specifi cally modifi ed substrate in vitro39, though RV was 
able to upregulate the Sirt1 enzyme in vivo.40 
2.2.5. Resveratrol and Angiotensin II
Ang II plays an important role in controlling cardiovascular homeostasis and development 
of cardiovascular diseases41. Previous studies of our groups showed already a regulatory 
effect of RV on Ang II-treated cells. In VSMC RV was able to inhibit proliferation and 
interfere with Ang II-induced hypertrophy.42-44 Publications using cardiomyocytes showed 
that Ang II-mediated hypertrophy was inhibited by ROS attenuation of RV45. Furthermore, 
RV was able to interfere with in vivo cardiac hypertrophy by modulation of NO and ET -1 
production.46 In cardiac fi broblasts an Akt-independent inhibition of proliferation and 
differentiation after Ang II treatment was detected by RV47. A recent publication showed 
that RV attenuated Ang II-induced interleukin (IL)-6 expression via suppression of the IL-6 
gene promoter activity.49
2.2.6. Bioavailability
Due to a rapid metabolism, RV has a short initial half-life of about 8 to 14 min50, 51. In vivo 
studies showed a very low intestinal uptake of RV and therefore minor concentrations in the 
blood due to extensive metabolism in the gut and liver52. When given intravenously, RV is 
converted to sulphate conjugates within ~ 30 min in humans53. Although the concentrations 
of trans-RV in red wine vary widely, a daily intake of 375 ml wine of a person weighing 
70 kg would correspond to a RV consumption of ~ 27 μg/kg per day when calculated with 
a RV content of 5 mg/l, leading to a plasma level concentration of up to 100 nM. A higher 
dose of red wine, however, could interfere with the benefi cial effects of RV as negative 
effects of ethanol increase.9 
We used a rather high dose of RV (50 μM) in our experiments, as the aim of this work was 
not to mimic physiological effects of RV but to investigate the molecular action of RV in 
VSMC.
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3. Angiotensin II
3.1. Physiological action
Angiotensin II (Ang II) is a potent growth factor in VSMC, known to induce hypertrophy 
but not hyperplasia in cultured VSMC.54 As the main player in the renin-angiotensin 
system (RAS), the vasoactive peptide angiotensin II (Ang II) is a potent enhancer of blood 
pressure via inducing vasoconstriction. As a critical hormone it further affects the function 
of all organs, including heart, kidney and brain. Clinical studies and pharmacological 
investigations about the effect of angiotensin-converting enzyme (ACE) inhibitors revealed 
that Ang II plays a central role in pathophysiology, inducing among others hypertension, 
cardiac hypertrophy, vascular thickening, and atherosclerosis.55-57 Ang II is triggering various 
actions in VSMC. Besides modulating vasomotor tone it regulates cell growth and apoptosis, 
infl uences cell migration and extracellular matrix deposition, acts proinfl ammatory and 
stimulates production of other growth factors (e.g. Platelet-derived growth factor PDGF) 
and vasoconstrictors (ET-1).56, 58-60 In rats chronic Ang II infusion leads to a hypertension 
and hypertrophy.61
3.2. Ang II receptors
The G protein-coupled Angiotensin type 1-4 receptors (AT1-4R) have been identifi ed as 
target receptors of Ang II. In VSMC the seven transmembrane regions containing-AT1-R is 
known to be responsible for most physiological effects. This receptor is widely distributed 
in all organs, like liver, adrenals, brain, kidney, lung, heart and vasculature.60, 62 Ang II-
induced hypertrophy in VSMC are mediated via the AT1-receptor (AT1-R), which can 
transactivate the epidermal growth factor (EGF)-, PDGF- and insulin-like growth factor 
(IGF) receptors. In rodents two subtypes named AT1A-R and AT1B-R are present, sharing 
94 % homology, whereas in humans only the AT1-R is found .63-64, 65 Short-time increase of 
Ang II leads to an elevated level of AT1-R activation. However, after chronic exposure to 
Ang II these receptors are downregulated.60, 66 When stimulated, the AT1-R is endocytosed 
within 10 minutes after activation. Approximately 25 % of the internalized receptors are 
recycled back to the plasma membrane, the remainder is degraded in the lysosomes.67, 68 
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3.3. Cellular signal transduction
After binding of Ang II to the AT1-R the signal can be transduced by activation of receptor 
tyrosine kinases (EGF-R, PDGF-R, IGF-R) and non-receptor tyrosine kinases (c-Src family 
kinases, Ca2+-dependent proline-rich tyrosine kinase 2 (Pyk2), focal adhesion kinase (FAK) 
and Janus kinases (JAK)).60 Findings also show that the activation of NAD(P)H oxidases 
and generation of reactive oxygen species (ROS) can be induced by Ang II stimulation69 
leading to activation of several serine/threonine kinases such as PKC, MAPK kinases 
(ERK1/2, p38 and c-jun N-terminal kinase (JNK))60, whereas other studies did not show a 
clear dependence of MAPK on ROS production58, 70, 71.
3.3.1. AT1-R related signaling
The AT1-R consists of seven transmembrane domains and interacts with multiple 
heterodimeric G-proteins (Gq/11, Gi, G12, G13) producing second messengers including 
ROS.72 The vasoconstrictor effect of Ang II is mediated by G-protein-coupled activation 
of downstream effectors like phospholipase C (PLC), phospholipase A2 (PLA2), and 
phospholipase D (PLD). Following PLC activation inositol-1,4,5-triphiosphate (IP3) and 
diacylglycerol (DAG) are produced within seconds, leading to calcium effl ux into the 
cytoplasm via IP3 binding and subsequently opening of Ca2+-channels on the sarcoplasmic 
reticulum. By recruiting Ca2+ to myosin light chain kinase (MLCK) the interaction between 
actin and myosin is increased, the VSMC contract.60, 65, 72 One main signaling pathway of Ang 
II is the MAP kinase pathway, including extracellular signal-regulated kinase (ERK1/2), 
JNK and p38, which cause VSMC differentiation, proliferation and migration.60, 73 ERK1/2 
is quickly activated by Ang II treatment via calcium-dependent kinase Pyk2 phosphorylation 
of Src and its adaptor protein Shc further leading to the formation of a Shc/Growth factor 
receptor binding protein (Grb2) complex. This in turn leads to recruitment of SOS (son 
of sevenless) and Raf, a scaffold protein which associates with the small GTP-binding 
protein Ras. Once activated Ras favours phosphorylation and subsequently activation of the 
MAPK/ERK kinase (MEK).41, 58, 60 In addition to MAPK activation Ang II stimulation also 
infl uences the apoptosis signal regulating kinase 1 (ASK1), which subsequently induces 
JNK and p38 related signaling74. Activation of the MAPK cascade infl uences cell survival, 
apoptosis and differentiation.75
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4. EGF and EGF-R
The family of epidermal growth factors (EGF) consists of several peptide growth factors76, 
among which EGF and heparin-binding EGF (HB-EGF) are known to bind to the EGF-
receptor (EGF-R). Before becoming active and binding to receptors, all members of this 
family have to be cleaved and only after processing by a disintegrin and metalloproteinase 
(ADAM) proteins the inactive precursor, a transmembrane protein, becomes active.77  HB-
EGF was found to be a chemoattractant produced by VSMC and macrophages and was also 
shown to infl uence migration and proliferation of VSMC. EGF is mainly secreted by bone 
marrow platelets, but capable of binding to the EGF-R of VSMC and EC.76 Effects of EGF 
Figure 3: Simplifi ed overview of the Ang II signaling in VSMC
Ang II regulates cell survival, growth and hypertrophy by activation of Noxes and subsequently 
transactivation of the EGF-R or activation of the MAPK pathway downstream of the AT1R 
directly. The EGF-R itself can activate the MAPK as well as the PI3K/Akt signaling pathway. 
Adopted from Metha P.K. et al60 and Higuchi S. et al72.
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appeared to be more effective in intimal VSMC than in medial SMC78. In the vasculature 
EGF and HB-EGF are important in atherogenesis as they mediate the transformation of 
VSMC from a differentiated non-proliferative into a dedifferentiated proliferative and 
migratory phenotype, supporting the development of atherosclerosis.76, 79 
The EGF-R is a prototype of the type-1 growth factor receptor family with tyrosine kinase 
activity. Four subtypes of EGF-R are known including ErbB1 (EGF-R, HER1), ErbB2 
(HER2, p185), ErbB3 (HER3, p160) and ErbB4 (HER4) and all of them are expressed in 
VSMC.80 The EGF-R can either be activated by binding EGF or HB-EGF, the production 
of the later is induced by Ang II stimulation. Upon ligand binding to the extracellular 
domain of the receptor a conformational change is induced leading to dimerization of the 
EGF-R monomers. Subsequently the fi ve important intrinsic protein tyrosines become 
autophosphorylated, activating the intrinsic EGF-R tyrosine kinase domain76, 80 Also 
transphosphorylation of the EGF-R by Src was shown81. The phosphorylated tyrosine 
residues on the receptor can be bound by Src homology 2 (SH2) domain-containing proteins, 
initiating the MAP kinase- and also PI3K-signaling pathway. Known binding partners of 
the EGF-R at distinct tyrosine residues at the C-terminus are: phospholipase C gamma 
(PLCγ), phospholipase D (PLD), Src, growth factor receptor-bound protein 2 (GRB2), 
GRB2-associated binder-1 (Gab-1), SH2-containing phosphatase-1 (Shp-1) and Ras76, 82, 83
The activation of the EGF-R is leading to various signaling cascades, e.g. ERK and p38 
activation has been shown to depend on EGF-R transactivation, whereas the JNK-pathway 
is EGF-R independent75. Another pathway, whose activation through the EGF-R is well 
established is the PI3K dependent phosphorylation of Akt.80
For the strength of the signaling not only ligand binding to the receptor but also the 
abundance of the receptor on the cell surface seems to be important. This can be infl uenced 
by the cell by receptor shuttling, internalization and degradation.84 At the membrane the 
EGF-R is found integrated into caveolae (cholesterol-rich membrane regions containing 
high amounts of the protein caveolin), although data in literature are contradictory85, 86. 
Ligand binding then leads to a EGF-R shuttling to lipid rafts (cholesterol-rich membrane 
regions), which are important for signaling as here several other signaling molecules are 
found co-localized.87 
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4.1. Transactivation of the EGF-R by Ang II
The EGF-R can not only be activated by stimulation with EGF directly. Also Ang II can 
rapidly transactivate the EGF-R88. In addition it was shown that also H2O2
89, endothelin90, 
thrombin91 , oxidized LDL92 and mechanical stretch93 can lead to an  activation of the EGF-R 
in cultured VSMC94. The EGF-R transactivation by Ang II requires ROS95 and upstream 
kinases such as c-Src or cAbl72, occurring in cholesterol-rich domains of caveolae96. Also 
evidence for a dependence on calcium were found60. The activation of c-Src and cAbl lead 
to release of HB-EGF by metalloproteinases (ADAMs)72. Recently ADAM17 was identifi ed 
in VMSC to be responsible for the transactivation97. The EGF-R is phosphorylated mainly 
at Tyr1173 and Tyr1068  by Ang II-induced ROS production.70, 95 Phosphorylated Tyr1068 is the 
binding site for the Grb2/Shc/SOS complex. This favours the activation of Ras/Raf/ERK1/2 
as well as the induction of the PI3K/phosphoinositide dependent kinase-1 (PDK1)/Akt 
cascade, inducing cellular metabolism, growth, survival and remodelling.60,72, 98
5. Insulin
Insulin is another peptide inducing VSMC proliferation and growth via the PI3K/Akt and 
MAPK pathway. It is a hormone synthesized and secreted in pancreatic β- cells in response 
to an increased level of glucose in the blood. By activating insulin receptors (IR) insulin 
controls glucose, lipid and protein metabolism. Similar to its homologous peptide insulin-
like growth factor (IGF-1) insulin also exhibits functions in the cardiovascular tissue such as 
increased vasorelaxation by stimulating NO release and reduced Ca2+ dependent contraction. 
Unlike insulin, IGF-1 can be produced by cardiomyocytes and VSMC themselves in response 
to Ang II and other growth factors or mechanical forces.99 Following the receptor activation 
members of IR substrate (IRS) family, consisting of IRS-1 to IRS-4, are phosphorylated100. 
Two major signaling pathways are then induced by insulin: the MAPK pathway and 
the PI3K/Akt pathway. The recruited IRS serves as docking protein for SH2 domain-
containing molecules such as PI3K, which interacts via its p85 regulatory subunit with 
the IRS, resulting in an increase of the catalytic activity of the p110 subunit. Also growth 
factor receptor binding protein 2 (Grb2) and Shp2 can bind the IRS, triggering the SOS 
induced activation of the Raf/MAPK cascade.101 The PI3K pathway is responsible for most 
metabolic actions of insulin, whereas the MAPK pathway regulates gene expression and 
cell growth.102 A connection of the Insulin signaling and Ang II signaling was discovered as 
Ang II inhibiting agents in insulin resistant patients did not only reduce blood pressure but 
– 17 –Introduction
Shc
IRS
P
PIP3PIP2
Ras
IR
P
SOS
Grb2
Raf
MEK
ERK 1/2
Cell proliferation and growth
SOS
Grb2
PI3K
Akt
Lipid synthesis
Glycogen synthesis
Protein synthesis
Glucose uptake
Figure 4: Insulin signaling pathway
A schematic overview of the signaling induced by Insulin binding to the insulin receptor 
(IR), which is leading to autophosphorylation of the receptor and subsequently recruitment 
of IRS and other molecules such as Shc. Activated downstream pathways contribute to lipid 
synthesis, glycogen synthesis, protein synthesis and glucose uptake. Adopted from Olivares-
Reyes J.A. et al102.
also improved insulin sensitivity102. In VSMC several reports show that Ang II can impair 
the insulin-mediated IRS-1 tyrosine phosphorylation and IRS-1/PI3K association103. Also 
an infl uence of Ang II on the insulin signaling by proteasome-dependent degradation of 
IRS-1 by Src, PDK1 and ROS-mediated phosphorylation of IRS was shown104.99 
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6. PI3K
The phosphatidylinositol 3´kinase (PI3K) is a key player for transducing signals downstream 
of the EGF-R, leading to an activation of Akt and mTor and subsequently hypertrophy83. 
As a kinase, it is able to phosphorylate the 3´-OH position of the inositol ring of 
phosphoinositides105. When activated the members of the Class I PI3K are phosphorylating 
phosphatidylinositol-4,5-bisphosphate (PIP2) to generate Phosphatidylinositol-3,4,5-
trisphosphate (PIP3), which are both bound to the membranes. Proteins, which possess the 
PH (pleckstrin homology) domain, are then recruited to the plasma or endosomal membrane 
by PIP3. Here they either transactivate other proteins or activate themselves106. The PI3K 
consists of a regulatory adapter subunit (p85) coupled to a catalytic subunit (p110α, β, γ)107 
PI3K activity is negatively regulated by two phosphoinositide phosphatases. One is the 
Src homology 2 (SH2) domain-containing inositide phosphatase  (SHIP), the second is 
phosphatase and tensin homolog deleted on chromosome ten (PTEN), both converting PIP3 
to PIP2105. In the EGF-R signaling PI3K is recruited to tyrosine phosphorylated adaptor 
protein Gab1, which is bound to Tyr1068 and Tyr1086 at the EGF-R. Gab1 is located at the 
plasma membrane via its PH domain and therefore PI3K is also recruited to the membrane 
by Gab1-binding, producing PIP3 out of PIP2. This is leading to more Gab1 recruitment 
to the plasma membrane as it can bind to PIP3 via its PH domain, favouring Gab1-PI3K 
recruitment leading to an increase of the signal via a positive feedback loop. 108,83
7. Akt
In response to growth factor and hormone stimulation the serine/threonine kinase Akt/
PKB is a critical signaling node in all higher eukaryotic cells. Three isoforms are known 
- Akt1 (PKBα), Akt2 (PKBβ) and Akt3 (PKBγ). They are highly homologous to protein 
kinases A, G and C, sharing the structure of their catalytic domain109. Akt1 is ubiquitously 
expressed, Akt2 is found predominantly in insulin target tissues such as fat cells, liver and 
skeletal muscle and Akt3 is rarely expressed, mainly in the brain110. Important properties 
of Akt are the PH domain, that allows the molecule to be recruited to the membrane, and 
the hydrophobic motif (HM) domain, acting as docking site for kinases such as PKC and 
p70S6K106, 109. Upon activation of receptor tyrosine kinases (RTK), scaffolding adaptors 
bind to the receptor, recruiting and activating PI3K that produces PIP3. Both, Akt and 
PDK1 can bind to PIP3 at the plasma membrane and PDK activates Akt by phosphorylation 
at Tyr308. In addition, also the so called kinase PDK2 is recruited which phosphorylates Akt 
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at Ser473. It is not absolutely clear at the moment, which kinase PDK2 really is but evidence 
is increasing that the mTOR complex 2 (mTORC2) is acting as PDK2.110-113 The fi rst known 
substrate of Akt was glycogen synthase kinase 3 (GSK3), which is keeping cell cycle-related 
targets as cyclin D, c-Myc and the eukaryotic initiation factor (eIF) 2B in a inactive status. 
Upon phosphorylation by Akt GSK3 is inactivated leading to cell cycle progression and 
protein synthesis114. The GSK3 was also found recently to modulate apoptosis favouring 
survival by inhibition of the Bcl-2 family member MCL-1 and interfering with caspase-
9 activation115 as well as BAD activation116. Akt mediates phosphorylation and export of 
members of the FOXO-family of forkhead transcription factors out of the nucleus causing 
their inactivation and therefore blocking target genes that promote apoptosis, cell-cycle 
arrest and metabolic processes106, 117;109. Moreover, Akt induces cell growth by mTORC1 
dependent activation of S6 kinase (S6K1) and eukaryotic initiation factor 4E (eIF4E)-
binding protein 1 (4E-BP1).109 Protein synthesis is regulated by Akt via mTOR dependent 
p70S6 kinase activation, inducing transcription factors AP-1 and E2F.105
8. MAPK 
The mitogen-activated protein kinases (MAPK) are a ubiquitous and highly conserved family 
of serine-threonine protein kinases activated by environmental stimuli including growth 
factors, cytokines, shear stress, vasoactive agents, and oxidative stress.118-120 Extracellular-
signal regulated kinases (ERKs), p38MAPK (p38α, p38β, p38γ, p38δ) and c-Jun N-terminal 
kinases (JNKs) are the three major members of this family and important for an injury 
caused vascular response. MAPK are regulated by phosphorylation; organised in a triple 
kinase pathway in which MAPK serve as substrates for MAPK kinases (MKK), which in 
turn are phosphorylated by MAPK kinase kinases (MKKK). When the EGF-R is activated, 
Grb2 and the constitutively associated SOS are recruited to the plasma membrane, where 
SOS catalyses the switch of membrane-bound inactive Ras to GTP-bound active Ras. p120-
RasGAP is a GTPase-activating protein containing SH2 domains that counteracts SOS-
dependent activation of Ras.121 Ras activates Raf1 which then phosphorylates ERK1/2 on 
a threonine and tyrosine residue.119, 122 Substrates of the activated ERK1/2 are found at the 
plasma membrane, in the cytosol and in the nucleus, leading for example to the induction of 
transcription factors Elk1, c-Myc and the p90 ribosomal S6 kinase123. The GTP-bound Ras 
can in addition activate JNK and p38 cascades, stress induced stimuli such as ROS were 
shown to activate JNK and p38 independent of Ras122. Importance for p38 and ERK1/2 
for aortic injury was indicated by several studies where balloon injury of rat carotid artery 
lead to a rapid activation of ERK1/2, p38 α/β MAPK and JNK 1/2, promoting neointima 
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formation and VMSC proliferation.124, 125 In the development of atherosclerosis JNK2 and 
p38 α activity is regulating the expression or activity of proteins required for internalization 
of oxLDL prior to their binding to cell-surface receptors.122, 126 
9. Protein tyrosine phosphatases (PTP) in the VSMC    
 signaling
In cells the response to external signals is often mediated by reversible phosphorylation of 
intracellular proteins. Protein tyrosine phosphatases (PTP) such as PTEN, DEP1, and Shp1 
gain more and more importance in cancer as tumour suppressor genes. The PTP Shp2 was 
identifi ed so fare as the phosphatase that acts as a proto-oncogene. 127 Phosphatases are also 
related to many other diseases including autoimmunity and developmental disorders.128 
Phosphatases are able to counteract the phosphorylation by removing the phosphates which 
were transferred to a protein by kinases before. Due to their specifi city for target amino 
acids the phosphatases can be divided into two major groups, the Ser/Thr phosphatases and 
the Tyr phosphatases, some phosphatases also possess dual specifi city. The PTP share the 
active-site signature motif HCX5R, including a cystein residue which is a nucleophile and 
essential for catalysis. 128-131 Due to their microenvironment the catalytic cysteins (C-S-) 
have a low pKa, and under normal conditions they form thiolate anions, highly susceptible 
to oxidation. The transfer of the phosphate moiety from the substrate to the catalytic cystein 
and rapid hydrolysis of the phosphate is important for the function of PTPs. When the cystein 
is oxidised its nucleophilic property is abrogated inhibiting of PTP activity. Many stimuli 
are already found to inactivate PTP transiently by producing ROS. The reversible oxidation 
leads to formation of sulphenic acid (C-SOH), whereas oxidation to sulphinic (C-SO2H) or 
sulphonic (C-SO3H) acids are usually irreversible.
132-134 To prevent cysteins from oxidation 
PTP can form a disulfi de bridge containing the catalytic cystein or sulphenic-amide bonds 
as it is the case for PTP1B130 or Shp2135. Transactivation of a receptor, like the Ang II 
induced activation of the EGF-R is often combined with H2O2 generation, resulting in PTP 
redox inactivation and consequently PTK redox activation. A redox dependent activation of 
the PDGFR by Ang II transactivation suggests to be dependent on redox activation of Src 
and Pyk2 kinases and also PTP redox inhibition.130, 136, 137 This tight regulation is achieved 
by a localized ROS production specifi cally inactivating a single phosphatase and varying 
among cells.131
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9.1. Src homology 2 (SH2) domain containing phosphatase 2 (Shp2)
One PTP important in the Ang II signaling in VSMC is the 68 kDa big cytosolic phosphatase 
Shp2. Together with its paralogue Shp1 it shares a specifi c structure unique in the PTP 
family, namely two SH2 domains positioned at the N-terminus of the molecule. This 
structure is followed by the catalytic domain and a C-terminal tail important for regulatory 
functions which contains tyrosine and serine phosphorylation sites.139, 140 In addition Shp2 
has a proline-rich domain that might bind SH3 domain-containing proteins like Src and 
Lyn, but lacks the nuclear localization sequence (NLS) Shp1 possesses. Shp1 is mainly 
known as negative regulator of signaling important for haematopoietic mechanisms, while 
Shp2 is regarded as a positively acting key factor in development since inactivation of 
RTK
PTP
P
P
ROS
PTP SOHSH oxidated/inactive
reduced/
active
AT1R
Nox Nox
reducing agents
Figure 5: ROS-mediated modulation of receptor tyrosine kinases (RTK) and protein 
tyrosine kinases (PTPs) in Ang II signaling
Tyrosine phosphorylation and subsequently activation of RTKs like the EGF-R can be 
promoted by ROS via inactivation of PTPs, leading to its activation. PTPs are catalytically 
inactivated by ROS-induced oxidation which can be reversed by reducing agents. Adopted 
from Chiarugi P. et al138.
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Shp2 in knock out experiments led to major developmental defects.121, 141 For the neointima 
development a regulatory effect of Shp2 is suggested as it was found to be upregulated 
during neointima formation in VMSC.142
9.1.1. Posttranslational modifi cation of Shp2 - oxidation and phosphorylation
The main ways of regulation of Shp2 are phosphorylation at the residues Tyr542, Tyr580, 
Ser576 and Ser591, oxidation of the cystein residue at the catalytic site140 or binding proteins 
via SH2 domains. Under basal conditions Shp2 is catalytically inactive due to SH2 domain-
mediated autoinhibition, as its N-terminal SH2 domain is inserted into the catalytic cleft139. 
By binding of the SH2 domains to a tyrosine phosphorylated ligand the PTP activity 
increases dramatically.130 The two tyrosine residues (Tyr542, Tyr580) are then susceptible to 
Figure 6: Shp2 structure and regulation
A, Schematic structure of Shp2. Shp2 contains two SH2 domains, a N-terminal and a C-
terminal SH2 domain, a catalytic PTP domain and a C-terminal tail containing two tyrosine 
residues. B, Potential mechanism of Shp2 regulation. In basal state Shp2 is largely inactive 
due to a “backside loop” of the N-SH2 inserted in the catalytic cleft. Phosphorylation at the 
two SH2 domains by either a SH2-binding protein (BP) or by binding the two phosphorylated 
residues Tyr542 and Tyr580 at the C-terminus leads to activation of Shp2 which results in 
induced binding and dephosphorylation of substrates (S). Adopted from Neel B.G. et al.143 
and Shen K.139 
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phosphorylation by different receptors and non-receptor protein tyrosine kinases (PTK) 
and other proteins including insulin response substrate-1 (IRS-1), and Gab1.143 Two major 
functions of Shp2 have been proposed including acting as adaptor to recruit proteins such 
as Grb2 and SHIP through their SH2 domains, as well as direct signal regulation via its 
phosphatase activity140. PKC activation leads to a serine phosphorylation of Shp1 and Shp2, 
but Shp2 activity seems not to be affected by this action.144 The tyrosine phosphorylation 
of Shp2 seems to be dependent on the stimulus, FGF and PDGF induce it, in contrast EGF 
seems not to do so, indicating a role for the phosphorylation in some but not all signaling 
pathways.145 Currently, it is unclear which of the tyrosine residues of Shp2 are important 
for the activity, as contradictory data is found in the literature.146, 147 As described above, 
Shp2 is prone to oxidation at the catalytic cystein residue, resulting in an inactive catalytic 
domain whereas redox regulation of Shp2 seems do be very much dependent on the cell 
type.148 A recent publication indicates a redox-dependent regulation of Shp2 by Ang II via 
oxidation and phosphorylation in VSMC.149 
9.1.2. Shp2 and EGF-R signaling 
Knock out experiments in mice suggest a pivotal role for Shp2 in the EGF-R signaling 
in vivo as Shp2 chimeric knock out cells show a phenotype similar to the EGF receptor 
knockout mice.150, 151 In EGF induced signaling docking sites for the phosphotyrosine-
binding domains (SH2), which also Shp2 possesses, is created by autophosphorylation of 
the EGF-R. In the EGF signaling it was shown that the EGF-R is dephosphorylated by Shp2 
on Tyr922, a RasGAP-binding site, abolishing the binding of this Ras inhibitor to the EGF-R 
and thus, excluding it from the EGF-induced signaling complex and promoting MAPK 
activation.121, 152 Later it was shown that this effect is mediated by dephosphorylation of 
the binding site for RasGAP on Gab1 by Shp2.153 In addition to the well known activation 
of MAPK after EGF stimulation Shp2 plays a role in the PI3K/Akt signaling pathway 
regulation. By dephosphorylation of Gab1 at the binding site for the PI3K subunit p85 
it can inhibit PI3K binding, leading to an inhibition of the Gab1-PI3K positive feedback 
loop, as shown by the interference of Shp2 with PI3K activity and Akt phosphorylation 
in fi broblasts.154 Activation of Shp2 by RV was shown in fi broblasts by our own group 
previously.44 A recent paper also connects Shp2 to Ang II signaling and the EGF-R by 
fi ndings in COS cells showing that Shp2 activity is important for the direct interaction of 
the AT1-R and the EGF-R.155 Recently also an interaction of c-Src and Shp2 was detected 
in endothelial cells after Ang II stimulation, infl uencing Nox and ERK1/2 activity.156
– 24 – Introduction 
10. ROS
Reactive oxygen species (ROS) are products of the normal cellular metabolism. In former 
times ROS was regarded as toxic compound, triggering apoptosis and cell damage. ROS was 
also found to be produced during the respiratory burst in neutrophils for bacterial killing. 
Nowadays a more complex view of ROS function is accepted as lower concentrations of 
ROS are involved in cell signaling, leading to cell growth and differentiation, to modulation 
of the ECM, and to inactivation of NO and many kinases. The concentration of ROS is 
kept below a toxic threshold by fi ne balance of oxidants and antioxidants in the cell.157,158 
Members of the ROS family normally contain unpaired electrons. The superoxide anion 
(O2
•-) is the so called “primary” ROS; produced in the vessels mainly by NADPH oxidases, 
the “secondary” ROS include hydrogen peroxide (H2O2), hydroxyl radical (OH
•) and nitric 
oxide (NO).159, 160 Other sources of ROS in VSMC are xanthine oxidase, lipoxygenase 
and nitric oxide synthase. H2O2 is cell-permeant, very stable and generated primarily by 
superoxide dismutase (SOD)-mediated dismutation of O2
•-.161, 162 Intracellular regulators 
of ROS are catalase and glutathione peroxidase (Gpx1). Catalase is found mainly in 
peroxisomes, catalysing the reaction of H2O2 to water, Gpx1 is located in the cellular 
cytosol and mitochondria, favouring also the detoxifi cation of H2O2 to water by producing 
glutathione disulfi de out of glutathione.161
10.1. ROS in Ang II signaling
ROS play an important role as mediators of Ang II signaling. Ang II-induced hypertrophy 
of VSMC is suggested to be NADPH oxidase-dependent163. H2O2 derived from NADPH 
oxidases was shown to be needed for the activation of c-Src164 and also transactivation 
of the EGF-R seems to be redox-dependent. The detailed mechanism is not known but 
Nox1 seems to be important for ROS production after Ang II treatment. Several kinases are 
susceptible to ROS, a redox regulation of p38 and JNK has been shown clearly, whereas 
the data for ERK1/2 are more contradictory.161 H2O2 treatment was shown to induce the 
phosphorylation of Akt166 and this phosphorylation is further thought to be redox regulated 
as p38 can phosphorylate and recruit MAPKAPK-2 to the Akt/p38 complex, leading to a 
phosphorylation of Akt on Ser473.167
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11. NADPH oxidases
Nicotinamide adenine dinucleotide phosphate (NADPH) oxidases, in short “Noxes”, are 
the most important producers of ROS in VSMC. The only ROS source in mammalian cells 
was thought for a long time to be the NADPH oxidase of phagocytes (Phox), found mainly 
in neutrophils and macrophages where it catalyses the respiratory burst. The function 
of the Nox there is to produce large amounts of superoxide upon exposure of the cell to 
microorganisms or stimulation by infl ammatory mediators.162, 168, 169 In other cells Noxes 
were found to produce ROS in a rather regulated manner. There are at least three different 
Noxes present in the vasculature: Nox4 is expressed ubiquitously, Nox1 is highly expressed 
in VSMC and Nox2 is mainly expressed in endothelial cells and cardiomyocytes.170,171 Table 
I shows the expression of different Noxes in tissues.168, 172, 173 
High level of expression
Nox1
Nox2
Nox4
Nox5
colon epithelial cells, VSMC, endothelium 
phagocytes, endothelium, cardiomyocytes
endothelium, VSMC, kidney, osteoclasts
lymphoid tissue, endothelium,  VSMC,
Activation
constitutively active
inducible
inducible
inducible
Nox3 constitutively active ? inner ear, fetal kidney, fetal spleen
Table I: Nox expression in tissues
11.1. Structure and activation
The Nox2 protein (also called gp91phox) was the fi rst Nox identifi ed in phagocytes. 
Meanwhile seven other Nox family members were found, all of which are important for 
the ROS production.172 The Nox prototype is a membrane-integrated glycoprotein which 
further contains two hemes in the NADPH-binding site located at the very COOH terminus, 
and FAD-binding domains are located in the cytoplasmic region, making it capable of 
transporting electrons from NADPH via FAD to molecular oxygen.174 Homologues of 
gp91phox in human and animals are called Nox1-Nox5. In addition there were also dual 
oxidases (Duox) found, named Duox1 and Duox2, which are Ca2+ dependent and contain a 
peroxidase-homology domain. This enables Duox to both generate reactive oxygen and use it 
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through its own peroxidase domain169, 171, 175 In animals Nox1-Nox4 form a heterodimer with 
the membrane protein p22phox, a complex known in phagocytes as fl avocytochrome b558. 
The activation of Nox1 and Nox2 by interaction with p22phox together with the cytosolic 
subunits leads to a production of superoxide by sequential transfer of two electrons from 
NADPH to molecular oxygen.165, 169
11.2. Nox1
Ang II was the fi rst reagent shown to stimulate ROS production via Nox1 activation in 
rat VSMC using it in pathophysiologically relevant concentrations.162,176 The main ROS 
species produced by this pathway is superoxide (O2
•-)177, 178 Activation of the membrane 
bound Nox1 protein is dependent on the interaction with p22phox, an other membrane-
located protein, and recruitment of the cytosolic subunits p47phox and p67phox or their 
homologues to the Nox1 complex via their SH3 domain. In addition the interaction of 
the small GTPase Rac with the other Nox subunits is important for activation. p47phox is 
thought to organize the translocation of the other cytosolic factors to the membrane and 
therefore its homologues are designed as “organizer subunit” (NOXO1). After translocation 
to the membrane p67phox, the “activator subunit”, or its homologue NOXA1, are then 
activated by contact to Nox1 and this subsequently leads to Rac interaction with Nox1.172 
In VSMC the involvement of p67phox or NOXA in Nox1 activation is not well defi ned in 
literature.172, 179
The detailed mechanism of Nox activation by Ang II is not absolutely clear. It was 
shown that the activation of p47phox via phosphorylation by protein kinase C (PKC) and 
subsequently translocation of the membrane is needed.179 Upon stimulation with Ang II 
the AT1-R binds to caveolin-1 leading to traffi cking of the AT1-R from high-density non-
caveolar membrane fractions into caveolin-1-containing caveolae/lipid rafts where Nox1 
can be found. Rac1 has to be activated and recruited to caveolae/lipid rafts for maintaining 
the Nox activity.176, 178, 180 Possibly Rac is activated by c-Src via activation of c-Abl and 
SOS-1 that in turn translocates Rac to the lipid rafts and activates it.181 A role for PI3K 
in Rac-1 activation is suggested since Ang II-triggered ROS release can be inhibited by 
PI3K inhibitors.164 Finally, this localized ROS production seems to be necessary for EGF-R 
transactivation.178
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Figure 7: Structure and activation of Nox1 in VSMC
For the activation of Nox1 in VSMC the cytosolic subunits p47phox (NOXO), Rac and 
possibly also NOXA (p67phox) have to be translocated to the two membrane-bound subunits 
Nox1 and p22phox. The activation results in the formation of superoxide (O2
•-), which is 
dismutated by the superoxide dismutase (SOD) to hydrogen peroxide (H2O2). The intracellular 
antioxidant catalse can decompose H2O2 to oxygen and water. ROS regulates the expression 
and activation of several mediators of cardiovascular disease. Adopted from Guzik T.J. et 
al180, Cai H. et al162 and Garrido et al179.
Also other stimuli were shown to activate Nox1. Proliferation of VSMC in response to 
growth factors like urokinase plasminogen activator (uPA) was shown to be dependent 
on Nox1182, 183. Basic fi broblast growth factor (bFGF)184 and PDGF induced migration was 
shown to be is Nox1-related185. In addition, in VSMC Nox1 was shown to contribute to 
p38 and Akt activation186.165, 171 Nox1 knock out mice were shown to develop less Ang  II-
induced hypertension187, whereas confl icting observations were made concerning Nox1 
involvement in hypertrophy.187, 188 
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11.3. Nox4
For Nox4 activation only binding of p22phox to Nox4 is needed rendering Nox4 
constitutively active. Rac binding to the complex seems not to be important but fi ndings in 
the literature are controversial 189,131. Therefore Nox4 is responsible for the basal ROS level 
in VSMC, and it was shown that Nox4 is important for the maintenance of the differentiated 
phenotype of the VSMC. 190 In contrast to other Noxes, the main ROS produced by Nox4 
after Ang II treatment is hydrogen peroxide (H2O2).
177
Studies show that after vascular injury, during hypoxia and serum deprivation the Nox4 
protein expression was strongly induced.171, 184 Other data indicated that stimuli like 
Ang II, thrombin and PDGF induce Nox1 expression but down regulate Nox4 expression 
level.168, 171,165 In contrast to Nox1 which is always membrane bound Nox4 was found recently 
in distinct subcellular locations in VSMC, mainly in the nucleus and at focal adhesions 
where also activated EGF-R, PI3K and Src can be found.95, 181, 191 When the EGF-R and cave 
olin-1 are phosphorylated due to a growth factor signal by c-Src they appear together with 
Nox4 and paxillin at focal adhesions, supposedly forming a redox signaling platform.178
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12. Aim of the work
In the western world cardiovascular disease (CVD) is the leading cause of death.2, 192 One 
important factor contributing to the development of this disease is angiotensin II (Ang II). 
Ang II acts as a potent vasoconstrictor and growth factor and can promote endothelial 
dysfunction.55 In vascular smooth muscle cells (VSMC), Ang II promotes cell growth 
(hypertrophy).54 It was recently shown that resveratrol (RV) inhibits Ang II-induced 
hypertrophy in VSMC by interfering specifi cally with the PI3K/Akt pathway 42. The main 
site of action was reported to be downstream of the epidermal growth factor-receptor 
(EGF-R) that was activated either by EGF stimulation directly or via transactivation of 
the receptor by Ang II. In fi broblasts, evidence was found that RV increases the activity 
of the redox-sensitive SH2-domain containing phosphatase 2 (Shp2)44. As active Shp2 can 
dephosphorylate the PI3K binding site at Grb-2 associated binder (Gab) 1 and therefore at 
the EGF-R, PI3K recruitment to the receptor is impaired and Akt activation is hampered154 
(Fig. 8). The current work is based on the hypothesis that RV can restore Shp2 activity 
by interfering with reactive oxygen species (ROS) produced downstream of the activated 
epidermal growth factor receptor (EGF-R) that is transactivated in VSMC in response to 
Ang II. Inhibition of ROS production will prevent oxidation and thus inhibition of Shp2. 
Specifi c aims of this thesis were to:
(i) examine whether RV acts as antioxidant when inhibiting Akt phosphorylation in   
 Ang II- and EGF-activated VSMC.
(ii) identify the source of ROS potentially responsible for Akt activation downstream   
 of the EGF-R.
(iii) examine whether Ang II and EGF-triggered phosphorylation of Akt occurs redox   
 dependent.
(iv) verify the role of Shp2 as a RV target in VSMC and to determine whether RV   
 affects  Shp2 by a redox-sensitive mechanism.
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Figure 8: Hypothesis
The EGF-R can be activated either by EGF stimulation directly or by Ang II-mediated 
transactivation. In fi broblasts it was shown that Shp2 can dephosphorylate the PI3K binding 
site at Gab1, leading to impaired PI3K recruitment to the receptor and subsequently inhibition 
of Akt activation.154 RV could infl uence Shp2 activity by reducing ROS produced by Noxes 
upon stimulation.
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C Material and Methods
1. Chemicals and buffers
All chemicals were obtained from Sigma Aldrich (St. Louis, MO, USA) and Carl Roth 
(Karlsruhe, Germany).
2. Cell culture
2.1. Isolation
Vascular smooth muscle cells (VSMC) were isolated from three different aortas of male 
Sprague-Dawley rats. The aortas were excised from rats and placed in PBS +, then cleaned 
from connective tissue and incised longitudinally. After incubation in digestion buffer 
for 15 min at 37 °C the adventitia and the endothelium were scrapped off and the aortas 
were minced. The aortas were incubated in digestion buffer at 37 °C for 3 h to complete 
the enzymatic digestion. Afterwards the cells were pelleted by centrifugation (10 min, 
1100 rpm, 25°C) and seeded with growth medium in a 25 cm2 fl ask. The cells were verifi ed 
as VSMC by fl uorescence microscopy using a monoclonal anti-α-smooth muscle actin 
FITC-conjugated antibody (1:250 dilution, Sigma).
2.2. Cultivation
Cells were cultured at 37 °C and 5 % CO2 in a phenol red-free Dulbecco’s modifi ed Eagle’s 
medium (DMEM) supplemented with 10 % calf serum (CS), 2 mM glutamine, 100 U/ml 
penicillin and 100 μg/ml streptomycin. VSMC were passaged twice a week, grown at about 
90 % confl uence. For harvesting cells were treated with trypsin/EDTA, reaction was stopped 
with 10 % CS containing DMEM followed by centrifugation for 4 min at 1,400 rpm. Then 
cells were seeded in 75 cm2 fl asks. For experiments cell passages 7 to 14 were used, plated 
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Cell culture media and reagents
Name Provider
Dulbecco’s Modified Eagle Medium (DMEM),
5 g/L glucose, w/o L-glutamine, w/o phenolred
Lonza Group Ltd. (Basel, Switzerland)
Penicillin/streptomycin mixture
(10,000 U/ml potassium penicillin/
10,000 μg/ml streptomycin sulphate)
Lonza Group Ltd. (Basel, Switzerland)
Lonza Group Ltd. (Basel, Switzerland)L-glutamine 200 mM
Trypsin/EDTA  (1:250) 
Calf serum Lonza Group Ltd. (Basel, Switzerland)
Invitrogen (Carlsbad, CA, USA)
Table II: Cell culture reagents
in 6-well plates, 6 cm, 10 cm or 20 cm dishes. For stimulation the cells reached a confl uence 
of 60 - 80 %. Prior to stimulation cells were serum-starved with DMEM containing 0.1 % 
calf serum for 24 h.
2.3. Storage
For freezing VSMC were pelleted by centrifugation, resuspended in ice-cold freezing 
medium (containing 10 % DMSO). Approximately 1 x 106 cells/ml were frozen in 
cryovials, fi rst at -20 °C for one day, then -80 °C for three days before they were stored in 
liquid nitrogen at -196 °C. When thawing the cells the cryovial was warmed to 37 °C and 
immediately suspended in warm growth medium, pelleted by centrifugation to remove the 
trypsin and seeded in 75cm2 fl asks.
Prior to usage the calf serum (CS) was inactivated by heating to 56 °C for 30 min. Aliquots 
were stored at -20 °C.
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Solutions for cell culture
Solutions: cell culure Reagents
Table III: Cell culture solutions
PBS pH 7.4 NaCl
Na2HPO4
KH2HPO4
ddH2O
7.2 g
1.48 g
0.43 g
ad 1000 ml
Trpysin/EDTA in PBS (T/E) Trypsin
EDTA
0.05 %
0.02 %
Freeze medium DMEM
Calf Serum (CS)
DMSO
8.0 ml
2.0 ml
1.1 ml
PBS+ NaCl
Na2HPO4
KH2HPO4
ddH2O
KCl
MgCl2 x 6 H2O
CaCl2 x 2 H2O
8.0 g
0.2 g
1.15 g
0.2 g
0.1 g
0.1 g
ad 1000 ml
Growth medium DMEM
Calf Serum (CS)
Penicillin/Streptomycin
L-glutamine
500 ml
10 %
100 U/ml/100 μg/ml
2 mM
Digestion buffer 0.1 g
0.24
0.005 g
0.005 g
0.1 g
Collagenase (246 U/mg)
HEPES
Ascorbic acid
Gentamicin sulphate
BSA
Ham’s F12 medium (PANTM biotech)
Starving medium DMEM
Calf Serum (CS)
Penicillin/Streptomycin
L-glutamine
500 ml
0.1 %
100 U/ml/100 μg/ml
2 mM
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2.4. α-actin staining of VSMC
For identifi cation of VSMC the cells were stained with a FITC-conjugated anti-α-smooth 
muscle actin antibody. Cells were grown on cover slips for which they were transferred into 
12-well plates and 2 x 105 cells/well were seeded on them. After growing over night the 
cells were washed once with ice-cold PBS and then fi xed with methanol/acetone (1:1) for 
15 min at 4 °C. Cells were washed twice with PBS and incubated with the anti-α-smooth 
muscle actin antibody for 60 min at 4 °C. Before fi xing the VSMC-containing cover slips 
on a microscopy slide the cells were washed again with PBS. Pictures were taken with an 
Olympus BX51 microscope, using the FITC fi lter at a 400-fold magnifi cation.
2.5. Solutions for treatment of VSMC
VSMC were grown in 6 cm, 10 cm or 20 cm dishes until they reached about 60 – 80% 
confl uence. Then they were stimulated with Ang II, EGF, Insulin or H2O2 for the indicated 
times. RV, inhibitors and blocking peptides were normally preincubated 30 min before 
stimulation if not stated otherwise. Control cells were treated with 0.1 % DMSO as vehicle 
control when RV was used.
2.5.1. Ang II solution
Ang II (Sigma) was dissolved to a 2 mM stock solution in 0.25% BSA in PBS, stored at 
-80 °C. For working aliquots, then stock solution was diluted in 0.25% BSA to a concentration 
of 20 μM and stored at -20 °C. All experiments were performed using 100 nM Ang II for 
10 min, when not noted otherwise.
2.5.2. EGF
The EGF (Upstate) solution was prepared in PBS at a concentration of 100 μg/ml and 
stored at -20 °C. For experiments cells were stimulated with 100 ng/ml for 5 min unless 
stated differently. 
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2.5.3. Insulin
An Insulin solution from bovine pancreas (10 mg/ml, Sigma-Aldrich) was used and diluted 
prior to stimulation to a concentration of 100 nM in DMEM without supplements.
2.5.4. Resveratrol and its derivatives
A trans-Resveratrol (Sigma) stock solution with a concentration of 100 mM was prepared 
in DMSO and stored at -80 °C. For treatment of the cells RV in a fi nal concentration of 
50 μM was preincubated with the cells for 30 min.
The resveratrol derivatives Tri-O-methylresveratrol (TM-RV) and 3,5-Dihydroxy-
4´-methylstilben (R1) were synthesized by the group of Prof. Erker (Department of 
Pharmaceutical Chemistry, University of Vienna) and dissolved as described above.
Inhibitors and antioxidants
Name Provider
Table IV: Inhibitors and antioxidants
Concentration
Wortmannin NEB50 nM
DPI 10 μM Sigma
SigmaSirtinol 10 μM
NAC 10 mM Sigma
AG 1478 (Tyrphostin) Sigma250 nM
Sigma/Caslods-tat control 100 μM
Indirubin-3’-monoxime 3 μM Laurent Meijer (Roscoff)
50-200 μM CaymanEUK 134
gp91 ds-tat 100 μM Caslo
MnIII TM 50-200 μM Cayman
AEBSF 10 μM - 1 mM Sigma
MPG 50-300 μM Sigma
DMTU 50 μM - 10 mM Sigma/Fluka
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Blocking peptides
SequenceNox1
[H]-RKKRRQRRRCSTRIRRQL-NH2gp91 ds-tat
ds-tat control [H]-RKKRRQRRRAGAGAGAGA-NH2
3. Protein lysates
Cells were stimulated as described, then put on ice, washed twice with ice-cold PBS and 
freshly prepared lysis buffer (110 μl/6 cm dish) was applied on the cells immediately. Cells 
were lysed on ice at 4 °C for 30 min; proteins were scraped off and lysates were cleared of 
all cell components by centrifugation at 13,000 rpm for 10 min at 4 °C. After taking a small 
volume for protein quantifi cation supernatant was diluted 1:3 with 3 x SDS sample buffer 
(containing 15 % 2-mercaptoethanol), boiled for 5 min at 95 °C and stored at -80 °C.
Buffers for protein lysates
Solutions Reagents
Table VI: Buffers for protein lysates
Lysis buffer (stock solution)   HEPES     50 mM
     NaCl      50 mM
     NaF     50 mM
     Na4HP2O7 x 10 H2O    10 mM
     EDTA        5 mM
     Na3VO4       1 mM
     ddH2O      add 430 ml,
          pH 7.5
3x sample buffer    WB sample buffer stock    850 μl
     2-mercaptoethanol    150 μl
Prior to use    Stock solution    4.3 ml
     PMSF 0.1 M      50 μl
     CompleteTM 25x    202 μl
     Trition X-100 (10%)   500 μl  
WB sample buffer stock    Tris-HCl (0.5 M; pH 6.8)    37.5 ml
     SDS      6.0 g
     Glycerol     30 ml
     Bromphenol blue    15.0 mg
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3.1. Protein quantifi cation
The amount of protein was determined using the method of Bradford.193 The protein lysates 
were diluted in ddH2O 1:10. 10 μl were transferred into a 96-well plate, each sample was 
measured in triplicates. A standard curve with BSA (50-500 μg/ml) was prepared and 190 μl 
Bradford dilution was added to standards and samples. The plate was incubated for 5 min 
and the absorbance at 595 nm was measured using a Tecan SunriseTM microplate reader.
3.2. Immunoprecipitation
Cells were seeded in 10 cm dishes and stimulated as described. Proteins were solubilized 
with 500 μl lysis buffer/10 cm dish and cleared by centrifugation at 13,000 rpm for 10 min 
at 4°C. Homogenates were incubated with the primary antibody (1 μg anti-Shp2) over night 
at 4 °C followed by 3 h incubation with 30 μl Protein A/G PLUS-Agarose beads (Santa 
Cruz), which were diluted 1:1 in PBS. Beads were spun down and washed three times with 
lysis buffer before adding 20 μl sample buffer (15 % 2-mercaptoethanol).
4. SDS-PAGE and Western Blotting
4.1. SDS-PAGE
 
To separate the protein samples a sodium dodecyl sulphate-polyacrylamide gel electrophoresis 
(SDS-PAGE) according to Laemmli was performed.194 Therefore polyacrylamide (PAA) 
gels were polymerized using a 30 % solution of PAA/0.8 % bisacrylamide and a Mini-
PROTEANTM 3 Cell System (BIO-RAD). Final concentration of all used gels was depended 
on the molecular weight of the protein of interest. Mainly 10 % gels were used. The gel was 
loaded with equal amounts (20 μg) of proteins which were separated by electrophoresis at 
30 mA/gel for up to 2 h.
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4.2. Western blotting and detection
The separated proteins were transferred to a PVDF membrane using the tank blotting 
technique by applying 100 V for 90 min in a Mini Trans-BlotTM Electrophoretic Transfer 
Cell System (BIO-RAD). Membranes were then blocked with 5 % fat-free milk powder 
Gels, buffers and reagents for SDS-PAGE and Western blotting
Solutions Reagents
Table VII: Gels, buffers and reagents for protein seperation and detection
Resolving gel (10 % PAA)   Roti®-Phorese Gel 30    5 ml 
     ddH2O      6.10 ml
     Tris-HCl (1.5 M; pH 8.0)    3.75 ml
     SDS 10 %     0.15 ml
     TEMED     15 μl
     Ammonium persulfate 10 %   75 μl
Stacking gel     Roti®-Phorese Gel 30    1.7 ml
     ddH2O      7.0 ml
     Tris-HCl (1.25 M; pH 6.8)   1.0 ml
     SDS 10 %     0.1 ml
     TEMED     20 μl
     Ammonium persulfate 10 %   100 μl
5x Blotting buffer    Tris-base     15.2 g
     Glycine      72.9 g
     ddH2O      ad 1000 ml 
5x Electrophoresis buffer   Tris-base     15 g
     Glycine      72 g
     SDS      5 g
     ddH2O      ad 1000 ml
Blotting buffer     5x blotting buffer    200 ml
     Methanol     200 ml
     ddH2O      ad 1000 ml
TBS-T pH 8.0     Tris-base     3.0 g
     NaCl      11.1 g
     Tween-20     1 ml
     ddH2O      ad 1000 ml
Home-made ECL    ddH2O      4.5 ml
freshly prepared prior to use   Tris-base (1 M; pH 8.5)    0.5 ml
     Luminol (0.25 M in DMSO)   25 μl
     p-coumaric acid (90mM in DMSO)  11 μl
     H2O2 30 %     3 μl
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in TBS-T for at least 1 h and washed three times with TBS-T for 10 min. Specifi c primary 
antibodies were added to the membranes and incubated at 4 °C overnight. Before adding 
horseradish-peroxidase conjugated secondary antibodies the membranes were washed three 
times with TBS-T for 10 minutes. The secondary antibodies were incubated for at least 1 
h at room temperature. The membranes were washed again three times with TBS-T before 
visualization of the protein bands using ECL-solution to detect proteins with a LAS-3000TM 
(Fujifi lm) luminescent image analyzer. The band intensity was determined by densitrometric 
analysis using AIDA software (raytest).
Antibodies were diluted in TBST-T, 5 % milk or 5 % BSA according to the recommendation 
of the provider.
Antibodies and beads
Table VIII: antibodies and beads
Akt     rabbit, pc       1:1000         New England Biolabs (Beverly, MA, USA)
phospho Akt S473   rabbit, pc       1:1000         New England Biolabs (Beverly, MA, USA)
Erk1/2     rabbit, pc       1:1000         New England Biolabs (Beverly, MA, USA)
phospho Erk1/2 Y202/204  rabbit, pc       1:1000         New England Biolabs (Beverly, MA, USA)
Oxidized PTP Active Site  mouse, mc    1:500            R&D Systems (Minneapolis, MN, USA)
p38     rabbit, pc       1:1000         New England Biolabs (Beverly, MA, USA)
p85 (PI3K)   rabbit, pc       1:1000         Upstate (Charlottesville, VA, USA)
phospho p38 Y180/182   rabbit, pc       1:1000         New England Biolabs (Beverly, MA, USA)
SH-PTP2 (C-18)   rabbit, pc       1:1000         Santa Cruz (Santa Cruz, CA, USA)
phospho-SHP-2 Y542   rabbit, pc       1:1000         New England Biolabs (Beverly, MA, USA)
α-smooth muscle actin-FITC  mouse, mc    1:250            Sigma Aldrich (St. Louis, MO, USA)
tubulin     mouse, mc    1:1000          Santa Cruz (Santa Cruz, CA, USA)
  Protein A/G PLUS-Agarose (IP)                 Santa Cruz (Santa Cruz, CA, USA)
Target Source Dilution Provider
rabbit IgG    goat           1:2500        New England Biolabs (Beverly, MA, USA)
mouse IgG    goat           1:2500        Upstate (Charlottesville, VA, USA)
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5. ROS detection 
5.1. Intracellular ROS detection with FACS
Intracellular ROS was detected using 2’,7’-dichlorodihydrofl uorescein diacetate (H2DCF-
DA).195 This dye is a non-fl uorescent compound, which is able to cross the membrane 
and enter the cell. Once in the cell the cellular esterase cleaves the dye producing 2’,7’-
dichlorofl uorescein (H2DCF) which is unable to pass membranes again. This form 
can be easily oxidized by intracellular ROS leading to the fl uorescent product 2’,7’-
dichlorofl uorescein (DCF) and monitored by fl ow cytometry (FACS).
In 6-well plates 0.25 x 106 cells/well were seeded and grown for 24 h, then starved with 
DMEM (0.1 % FCS) for additional 24 h. Cells were washed with warm HBSS-buffer 
(37 °C), then HBSS was added to each well followed by preincubation with inhibitors 
(RV, DPI, NAC) for indicated times. As vehicle control 0.1 % DMSO was used. After 
15  min cells were loaded with 20 μM H2DCF-DA fi nal concentration per well. Cells were 
stimulated after additional 15 min and then the buffer was aspirated, cells were trypsinized 
Solutions and buffers for ROS measurement
Solutions Reagents
Table IX: ROS detection solutions
FACS buffer pH 7.37    NaCl      8.12 g
     KH2PO4     0.26 g
     Na2HPO4     2.35 g
     KCl      0.28 g
     LiCl      0.43 g
     NaN3      0.20 g
     Na2EDTA     0.36 g
     ddH2O      ad 1000 ml
PBS/BSA 2 %     BSA dissolved in PBS
HBSS Buffer    NaCl     8.18 mg
     KCl     400 mg
     Na2HPO4     19.75 mg
     KH2PO4     50 mg
     CaCl2 x H2O    180 mg
     MgSO4     97.5 mg
     Glucose      1000 mg
     HEPES     4760 mg
     ddH2O     ad 1000 ml 
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and the reaction was stopped with 2% BSA in PBS. For detection an emission wavelength 
of 525 nm on the fl uorescence channel Fl1h was measured using a FACSCaliburTM (BD). 
The peaks were recorded at the FACS and geometric mean was analysed using CellQuestTM 
Pro software. 
5.2. Extracellular ROS detection using Amplex RedTM Assay
The assay was performed by Mario Kumerz (Doctoral student in our group) using the method 
described in his thesis (Mai 2009, Uni. Vienna). The non-fl uorescent compound Amplex 
RedTM (10-acetyl-3,7-dihydroxyphenoxazine; Invitrogen, CA, USA) was used which is a 
substrate of horseradish peroxidase (HRP) and is able to be converted into resorufi n in the 
presence of H2O2 in a 1:1 stoichiometry
196.
In brief, VSMC were grown in 24-well plates and serum-starved for 24 hours. Cells were 
washed once with prewarmed PBS before the KRPG buffer containing the Amplex RedTM 
reagent was applied to the cells. Plates were incubated for 15 minutes at 37°C before VSMC 
were stimulated with different compounds for 5 - 15 minutes. 80 μl of the supernatant was 
transferred into 96-well plates and produced resorufi n was measured in triplicates with a 
fl uorometer (Genios Pro, Tecan, Switzerland).
6. Oxidized PTP detection assay
To detect the oxidation of PTPs in cells a special protocol based on antibody against 
oxidized PTPs was used.197,198 First all reduced PTPs have to be protected effi ciently with 
the help of iodoacetic acid (IAA) to prevent a pervanadate mediated oxidation. Only the 
already oxidized PTPs should be prone for the later processing of the probes. Then the 
oxidized PTPs are reduced by treating the samples with dithiothreitol (DTT) to make them 
susceptible to the later incubation with pervanadate. The pervanadate is converting the 
PTP from a sulfenic form to a sulfonic acid form, which is an irreversible oxidized form. 
This sulfonic form can be detected with a specifi c antibody directed against the conserved 
motif VHCSAG of PTPs, containing the active-site cysteine after western blotting of the 
proteins. 
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Figure 9: Antibody-based oxidized PTP detection assay
Schematic overview of the method to detect oxidized PTPs with a specifi c antibody. After 
stimulation all reduced PTPs are protected for further oxidation by IAA treatment. Only 
oxidized PTPs are then reduced with DTT and converted from a sulfenic to an irreversible 
oxidized sulfonic acid form using pervanadate. The sulfonic form can be detected after 
western blotting of the probes with a specifi c antibody. Adopted from Persson C. et al197.
3.5 x 106 VSMC were seeded in a 15 cm dish, grown over night and starved with DMEM 
(0.1% CS) for 24 h. Prior to the experiment DMEM without supplements was added to the 
cells and then the cells were stimulated as described. The lysis buffer was degassed with 
a water-jet vacuum pump for 30 – 45 min and to half of the buffer IAA (100 mM fi nal 
concentration) was added, since IAA has to be protected from light during the following 
processing the samples were sheltered from light. The non-IAA treated samples represent 
the positive controls, refl ecting the total amount of possible oxidized PTPs in the probes. 
Therefore always two sample were stimulated the same way, one was lysed with IAA 
the other one without IAA in the lysis buffer. Before adding 750 μl lysis buffer to the 
dishes the cells were washed twice with ice cold PBS. After 10 min incubation of the cells 
with lysis buffer they were scrapped off and pelleted by centrifugation at 13,000 rpm (10 
min at 4 °C). To the supernatant a phosphatase specifi c antibody (anti-Shp2) was added 
(1.5 μg) and incubated for 2 hours at 4 °C followed by in incubation with 30 μl Protein 
A/G PLUS-Agarose beads (Santa Cruz) at 4 °C for one hour. The beads were spun down 
briefl y and then washed once with 500 μl lysis buffer and 3 times with 500 μl degassed 20 
mM Hepes buffer. To reduce the sulfenic form of oxidized cysteins in the PTP acitive site 
100 mM DTT (100 μl/probe) was added to the samples for 30 min and then beads were 
washed again three times with Hepes buffer. After that, lysates were treated with freshly 
prepared Pervanadate (100 mM) at a fi nal concentration of 100 μM for 1 h. Samples were 
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briefl y spun at 2000 rpm, the supernatant was discarded and 20 μl 3xSDS sample buffer 
was added to the beads and heated to 95 °C for 5 min. The probes were stored at -80 °C until 
processing by SDS-PAGE and western blotting. For the detection of the oxidized PTPs an 
Oxidized PTP active site antibody (R&D systems) was used at a concentration of 1 μg/ml. 
The primary antibody was applied over night, the secondary for 2 h at room temperature 
with TBS-T washing between primary and secondary antibodies and before detection.
7. siRNA knock down in VSMC
7.1. Transfection of VSMC
For knocking down a specifi c protein VSMC were transfected with siRNA. 0.5 x 106 cells 
were seeded in 6 cm dishes. 5 h after seeding the cells they were transfected, using siRNA 
specifi c against Nox4 (ThermoFisher Scientifi c) or a StealthTM siRNA kit (Invirtrogen) 
specifi c for Shp2 (rat PTPN11). As scrambled control, Negative control med GC (Invitrogen) 
was used. Oligofectamin (Invitrogen) was dissolved in warm Opti-mem® I (Gibco), mixed 
by vortexing and left at room temperature for 5 min. The siRNA was diluted to a fi nal 
concentration of 50 μM in warm Opti-mem® I and then the siRNA and Oligofectamine 
were mixed by pipetting up and down and incubated at room temperature for 20 min. Before 
adding the siRNA to the cells they were washed twice with Opti-mem® I and 1.67 ml of 
it were put on each well. Then 330 μl of the siRNA/Oligofectamine mix were added drop 
siRNA Sequences
Name
Table XI: siRNA sequences
Sequence
Nox4: 5-’ACUGAGGUACAGCUGGAUGUU-3’
5-’CAUCCAGCUGUACCUCAGUUU-3’
Seq 1 5-’UACUUGACACACUUGCUCUUCCCUC-3’
5-’GAGGGAAGAGCAAGUGUGUCAAGUA-3’
Seq 2
5-’UUUAGGAACGUCGAUGUCACAGUCC-3’
5-’GGACUGUGACAUCGACGUUCCUAAA-3’
Seq 3 5-’UCCACCAGGGAAUACUUAAUAUUGG-3’
5-’CCAAUAUUAAGUAUUCCCUGGUGGA-3’
Shp2:
sense
anti-sense
sense
anti-sense
sense
anti-sense
sense
anti-sense
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wise to each dish. The siRNA was left on the cells over night, the next day it was replaced 
by DMEM (10 % CS). For further experiments the cells were used 72 h after transfection 
with siRNA. Prior to an experiment the cells were starved with DMEM (0.1 %FCS) for 
24 h.
8. RNA isolation and PCR
8.1. RNA isolation 
VSMC were grown in 6 cm dishes and for the RNA isolation two dishes were pooled. Total 
RNA was isolated using peqGOLD total RNA Kit (Peqlab) according to the manufacturer’s 
protocol. Cells were lysed with provided lysis buffer and homogenized with the supplied 
shredder columns. Before applying the lysates to the binding columns they were mixed with 
70 % ethanol. After RNA binding to the columns they were washed and DNA was digested 
by on-column treatment with DNase. Again the columns were washed, dried and RNA was 
eluted in 50 μl RNase-free water. The quality of the RNA was controlled on a 1 % -agarose 
gel and by measuring the RNA concentration at 260 nm with a spectrophotometer 
(BioPhotometer; Eppendorf AG). 
Buffers for RNA gel
Solutions Reagents
10x TBE     Tris base     108 g
     Boric acid     55 g
     0.5 M EDTA pH 8.0    40 ml
     ddH2O      ad 1000 ml
10x sample buffer    Bromphenol blue    4.0 mg
     ddH2O      5.0 ml
     Glycerol     5.0 ml
Agarose gel 1 %    Agarose     1.0 g
SYBR Safe DNA gel stain   10,000 x conc (in DMSO) 
     added after boiling of the agarose 
Table XII: Buffers for RNA gel
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The quantity is correlated to the absorbance at 260 nm and can be calculated using the 
following formula:
RNA concentration (μg/mg) = Absorbance260 x 40 x dilution factor
8.2. Reverse transcription
To analyse the RNA with the PCR technique RNA was converted to a complementary-
DNA (cDNA). For this purpose SuperscriptTM II Reverse Transcriptase (Invitrogen) and 
reagents provided with the SuperscriptTM First-Strand Synthesis System (Invitrogen) were 
used. The RT reaction was performed using 2 to 5 μg RNA , 10 ng random hexamers/μg 
RNA, 1 μl 10 mM dNTP mix (deoxyribonucleotides), 1 μl luciferase RNA (108 copies, 
exogenous standard) and fi lled to a total volume of 12 μl with RNase-free water. Samples 
were incubated at 65 °C for 5 min for denaturation, left on ice for 1 - 2 min and 4 μl 5x fi rst 
strand buffer, 2 μl DTT (0.1 M) and 1 μl RNaseOUT inhibitor (40 U/μl) were added. This 
mix was left at room temperature for 2 min in order to allow primers to anneal. Then 1 μl 
SuperscriptTM II RT enzyme (50 U/μl) was added. After incubated at 42 °C for 60 - 90 min 
the enzyme was inactivated by heating the samples to 70 °C for 15 min. To digest remaining 
RNA 1 μl RNase H was added to each tube for digesting remaining RNA. Finally the 
cDNA was purifi ed using Bio-Spin® 30 Tris Colums (BIO-RAD). Columns were dried by 
centrifugation at 1,000 g for two min to remove packing buffer. The cDNA was loaded on 
the resin drop wise and spun at 1,000 g for 4 min. cDNA was stored at -20 °C, for short time 
storage kept at 4 °C.
8.3. Quantitative real-time PCR
To quantify the expression level of a specifi c mRNA a quantitative real-time polymerase 
chain reaction (qPCR) was performed. For this purpose two gene-specifi c primers (forward 
and reverse) were used. Amplifi cation of DNA was detected using a LightCyclerTM LC480 
(Roche Diagnostics) system which detects fl uorescence of the dye SYBR® Green. This dye 
can only bind to double stranded DNA by intercalating with the minor groove of the DNA 
double helix. During the amplifi cation, the DNA amount increases exponentially, therefore 
also the signal increases the same way.
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The real-time PCR was carried out using LightCyclerTM LC480 SYBR Green I Master 
reagent (Roche Diagnostics). For target gene detection cDNA was diluted in RNase-free 
water 1:4, for the detection of the housekeeping gene (18 S RNA) a dilution of 1:1000 was 
made. The reaction mix contained 5 μl SYBR Green Master Mix, 0.5 μl primer solution 
(7.5 μM) for each primer and 8.5 μl PCR-grade water. 14 μl of the mixture was put into 
each well of a PCR plate and 1 μl cDNA was added, followed by a brief spin at 2,000 rpm. 
PCR was performed according to the manufacturer’s protocol and data were analysed using 
LightCyclerTM LC480 software.
9. Statistical analysis
All statistic analyses were performed with GraphPad PRISMTM software (GraphPad 
Software Inc). Data were normalized using stimulated samples as 100 % values. When 
comparing multiple treatment groups a one-way ANOVA combined with a Dunnett post 
test was accomplished. For comparison of two groups a two-tailed paired t-test was used. 
Values with p< 0.05 were considered as signifi cant and all graphs show ±SEM.
Primers for PCR
Table XIII: Sequence of primers used for PCR
Sequence
Nox1 CTG CTC TCC TTC CTG AGG GGC ACC TGC T
rev GAC AAT CCC CCC CAG GCC ATG GAT CCC TA
fwd
Gene Direction
CCG GGC CTG ACA GGT GTC TGC ATG GTG
CAC AGT ATA GGC ACA AAG GTC CAG AAA TCC AAA TCC AGG T
Nox4
rev
fwd
GAA TTG ACG GAA GGG CAC CAC CAG
GTG CAG CCC CGG ACA TCT AAG Grev
fwd18 S
GAA TTG ACG GAA GGG CAC CAC CAG
GTG CAG CCC CGG ACA TCT AAG G
Luciferase
rev
fwd
D   RESULTS
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Figure 10: Anti-α-smooth muscle actin staining of VSMC
Image shows VSMC immunostained with FITC-conjugated anti-α-smooth muscle actin 
antibody in 400-fold magnifi cation.
D Results
1. Characterisation of VSMC
Subcultured VSMC develop a proliferative phenotype resembling the cells in the neointima8. 
As shown by our group previously, Ang II induces hypertrophy in VSMC which could be 
inhibited by RV. The proposed mechanism was that RV activates Shp2, thus preventing 
interaction between Gab1 and PI3K that is necessary for the further activation of Akt.42, 44 
To further characterize the mechanism of this RV-mediated inhibition of Ang II signaling, 
we fi rst isolated VSMC from rat thoracic aortas as described in Material and Methods.
Smooth muscles have the unique ability to contract and relax in response to changes in 
the environment surrounding them. The so called “contractile actin” is important for the 
dynamic remodelling process.199 Therefore after isolation the identity of the VSMC was 
confi rmed by immunostaining with a FITC-conjugated α-smooth-muscle-actin antibody. 
By labelling specifi cally α-actin we could show the lattice-like structure of the actin fi lament 
systems (Fig.10).
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Figure 11: RV reduces Ang II- or EGF-induced phosphorylation of Akt
Quiescent VSMC were pretreated with 50 μM RV for 30 min and then stimulated with 
100 nM Ang II (A) for 10 min or 100 ng/ml of EGF for 5 min (B). Cells were lysed and 
protein detection was performed by western blot analysis using antibodies against pAkt 
and as loading control against tubulin. As vehicle control 0.1 % DMSO was used. One 
representative blot is shown.
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2. RV inhibits Akt phosphorylation upon Ang II and EGF   
 stimulation
Previous publications showed that RV can specifi cally inhibit Ang II- or EGF-induced 
Akt phosphorylation when preincubated with VSMC 30 min prior to stimulation.42, 44 We 
therefore fi rst of all verifi ed this effect in our experimental settings. Preincubation of cells 
with 50 μM RV for 30 min followed by stimulation with either Ang II (100 nM) for 10 min 
(Fig. 11A) or EGF (100 ng/ml) for 5 min (Fig. 11B) led to a diminished phosphorylation of 
Akt. Ang II stimulation normally led to a 2-4 fold increase of Akt phosphorylation, EGF 
treatment could elevate Akt phosphorylation even 10-fold.
3. Putative redox-related action of RV
3.1. Inhibition of intracellular and extracellular ROS by RV treatment  
 in VSMC
RV is well know for its antioxidative effects200 and therefore one aim of our study was 
to investigate whether RV acts as an antioxidant when inhibiting Akt phosphorylation. 
By inhibiting ROS, RV could lead to a restoration of the Shp2 activity by protecting it 
from oxidation explaining how RV is able to activate Shp2.44 A suggested mechanism for 
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Figure 12: RV diminishes intracellular ROS level after Ang II and EGF stimulation
Quiescent VSMC were incubated 15 min with 20 μM H2DCF-DA in HBSS buffer, then they 
were preincubated with 50 μM RV or 0.1 % DMSO (vehicle control) for 30 min or 10 μM DPI 
for 1 h and fi nally stimulated with 100 nM Ang II for 15 min (A) or with 100 ng/ml EGF for 
10 min (B). ROS production (equivalent to the amount of formed DCF) was analysed by fl ow 
cytometry. Graphs show average fl uorescent signal of three independent experiments. Ang 
II or EGF stimulation was set to 1 (**, p < 0.01; ns, not signifi cant; one-way ANOVA versus 
Ang II-or EGF-treatment).
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the antioxidative effect of RV would be a modulation of Noxes, potential ROS sources in 
VSMC. Therefore we used diphenylene iodium (DPI) as an unspecifi c inhibitor of fl avin-
containing enzymes including NADPH oxidases, xanthine oxidases and cytochrome P450 
enzymes201 as positive control to reduce ROS and to compare its impact with the effect of 
RV. It has been shown before that Ang II stimulation of VSMC leads to ROS production 
that contributes to VSMC-growth by activation of the p38MAPK cascade downstream of 
the AT1 receptor186 or by transactivation of the EGF-R through Nox dependent ROS60, 95.
To test, whether RV can inhibit Ang II- or EGF-mediated ROS production we loaded the 
cells with 20 μM H2DCF-DA, a dye which can be easily oxidized by ROS in the cell 
leading to a fl uorescent product, which can be measured with FACS for detection of 
intracellular ROS. Ang II stimulation for 15 min was able to induce ROS production double-
fold compared to the vehicle (DMSO) control. RV pretreatment was able to reduce ROS 
production nearly to basal levels (Fig 12A) and also preincubation with DPI, the positive 
control, inhibited ROS in accordance to literature.202 In contrast, treatment of the cells with 
100 ng/ml EGF for 10 min did not lead to a signifi cant activation of intracellular ROS 
production in comparison to the vehicle control (0.1 % DMSO). However, RV and DPI 
were able to inhibit the intracellular ROS levels by about 50 % (Fig. 12B), again verifying 
a strong antioxidant effect for both compounds.
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Figure 13: RV extenuates both basal and Ang II- or EGF-induced extracellular H2O2 
levels
(A) Serum starved VSMC were stimulated in Amplex Red buffer with EGF (100 ng/ml) 
for 5 to 15 minutes after preincuabtion with RV or vehicle control for 30 minutes. H2O2 
production was quantifi ed using a fl uorometer. Absolute values were correlated to catalase-
treated cells used as negative control. Graph shows relative extracellular H2O2 production 
expressed as x-fold vehicle-treated cells (–□–, vehicle-treated cells; –■–, RV-treated cells; 
***, p < 0.001; mean ± SEM; n = 4). (B) Cells were stimulated with Ang II (100 nM) and then 
treated and analyzed as indicated in (A). (–□–, vehicle-treated cells; –■–, RV-treated cells; 
***, p < 0.001; mean ± SEM; n = 4). For all statistical analyses, vehicle-treated cells were 
correlated to RV-treated cells for each time point separately.
Experiment was performed by Mario Kumerz (Doctoral student in our group, Thesis May 
2009, Uni. Vienna).
Upon EGF stimulation it was shown that H2O2 was produced extracellular after EGF-R 
transactivation, also infl uencing phosphatases.203 Examining extracellular H2O2  production 
in VSMC we applied an Amplex RedTM assay (performed by Mario Kumerz, Dissertation 
2009, Uni. Vienna), which is detecting extracellular produced H2O2.
In accordance with our intracellular ROS data we also observed a high level of extracellular 
H2O2 produced by unstimulated VSMC. Stimulation with Ang II and EGF was able to 
induce this production of extracellular H2O2 in a time-dependent manner (Fig. 13 A-B). 
EGF treatment led to a peak of H2O2 after 15 min (20 % above basal level). H2O2 production 
was highest 10 min after Ang II stimulation (15 % above basal level) but declined at later 
time points.
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Figure 14: Specifi c down-regulation of Nox4 in VSMC
Knock down was achieved by treating the cells with 50 μM siRNA against Nox4 or 50 μM 
scrambled control for 72 h. mRNA was isolated and expression of Nox4 was detected with 
real-time PCR. Graphs show mean Nox4 mRNA (A) or Nox1 mRNA (B) level relating to 18S 
mRNA levels of three independent experiments. Data were normalized setting scrambled 
control to 1 (***, p < 0.001; t-test).
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3.2. Role of Noxes in Ang II- and EGF-signaling in VSMC
RV acts as antioxidant in our cells as it was able to inhibit intra- and extracellular ROS 
levels. One major ROS source in VMSC are Noxes204 and therefore a suggested mechanism 
of RV-mediated ROS inhibition could be via infl uencing Noxes. In addition, RV has been 
shown to suppress Ang II-induced Nox activity in endothelial cells (EC)48. Nox 1 and Nox4 
are the two Nox proteins expressed in VSMC. Both have been shown to play a role in 
mitogenesis and hypertrophy in the cardiovascular system162, 168. Nox4 was detected in focal 
adhesions of VSMC where also the EGF-R is localized after tyrosine phosphorylation96, 
178, 205. In Ang II signaling in VSMC ROS production by Nox1 is suggested as the major 
component for the transactivation of the EGF-R95, 164, whereas the role of Noxes downstream 
of the EGF-R as well as the role of Nox4 in Ang II signaling is unclear.
3.2.1. Role of Nox4
3.2.1.1. Specifi c knock down of Nox4 mRNA in VSMC using siRNA 
To investigate whether Nox4 is important for the signaling after EGF or Ang II stimulation 
towards major kinases (Akt, p38, ERK1/2) Nox4 was inhibited by treatment with 50 μM 
siRNA for 72 h. By performing real-time PCR, the level of Nox4 mRNA was analyzed 
and a decline of Nox4 mRNA levels to 15 % compared to scrambled control treated cells 
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Figure 15: Ang II and RV-mediated inhibition 
of Akt, p38 and ERK1/2 phosphorylation is 
independent of Nox4
Serum-deprived Nox4 siRNA-treated cells were 
pretreated with RV (50 μM, 30 min) or 0.1 % 
DMSO followed by stimulation with 100 nM 
Ang II for 10 min. Phosphorylation of Akt (A), 
p38 (B) and ERK (C) was detected by western 
blot analysis. Densitometric analysis was per-
formed; mean protein levels of three indepen-
dent experiments are shown in the graphs. Ang II 
stimulation of scrambled control was set to 100 
% (**, p < 0.01;*, p < 0.05; ns, not signifi cant; 
one-way ANOVA versus Ang II-treatment).
was detected (Fig. 14A). In contrast, the mRNA level of Nox1 was not impaired by Nox4 
siRNA treatment (Fig. 14B), indicating a specifi c down-regulation of Nox4 mRNA by the 
used siRNA.
3.2.1.2. Nox 4 knock down does not infl uence phosphorylation of Akt after Ang II stimulation 
nor inhibition by RV
To test the infl uence of Nox4 knock down on the phosphorylation levels of several kinases 
in VSMC and on the RV-mediated inhibition, cells were treated with Nox4 siRNA (50 μM) 
or scrambled control siRNA (50 μM) for 72 h, then cells were stimulated as indicated 
and protein levels of pAkt, pp38 and pERK1/2 were detected by western blotting. Knock 
down of Nox4 had no impact on the phosphorylation of Akt after Ang II (100 nM, 10 min) 
stimulation, and also the inhibitory effect of RV (50 μM, 30 min) on phosphorylated Akt 
was not infl uenced (Fig. 15A). The phosphorylation level of p38 (Fig. 15B) and ERK 1/2 
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(Fig. 15C) was comparable to that of scrambled control treated cells. This excludes Nox4 
as a major source of ROS during Ang II stimulation by showing that Nox4 is not needed for 
the phosphorylation of Akt, p38 or ERK1/2. Furthermore RV seems not to act as a specifi c 
inhibitor of Nox4 as the knock down can not mimic the effect of RV on Akt phosphorylation 
nor blunt the inhibitory effect of RV.
3.2.1.3. VSMC with a Nox4 knock down show unaltered Akt phosphorylation in response 
to EGF treatment
Next the effect of EGF stimulation on Nox4 siRNA treated cells was investigated. Cells 
which were impaired in Nox4 expression by siRNA were pretreated with RV (50 μM, 
30 min) and stimulated with EGF (100 ng/ml, 5 min). Akt phosphorylation (Fig. 16A) 
as well as phosphorylation of p38 (Fig. 16B), and ERK1/2 (Fig. 16C) were analyzed by 
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Figure 16: EGF-induced phosphorylation 
of Akt, p38 and ERK1/2 is not infl uenced by 
knock down of Nox4 with siRNA
Nox4 diminished cells were serum-starved and 
then activated with 100 ng/ml EGF for 5 min after 
incubation with RV (50 μM) or 0.1 % DMSO for 
30 min. Proteins were detected by western blot-
ting with antibodies against pAkt (A), pp38 (B), 
and pERK1/2 (C). Tubulin was used as loading 
control. Graphs represent results from densito-
metric analysis of three independent experiments. 
EGF stimulation of scrambled control was set to 
100 % (**, p < 0.01;*, p < 0.05; ns, not signifi -
cant; one-way ANOVA versus EGF-treatment).
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western blotting. EGF stimulation led to activation of all three kinases comparable to the 
phosphorylation in the scrambled control cells which was inhibited by RV. Only the inhibition 
of ERK1/2 phosphorylation by RV was slightly diminished by Nox4 knock down.
These data indicate that Nox4 does not play a major role in Ang II- or EGF-induced MAPK 
and Akt phosphorylation in VSMC. Thus, Nox4 is no suggestive target of RV.
3.2.2. Role of Nox1
3.2.2.1. Nox1 suppression abolishes Ang II stimulation of Akt and p38
We next investigated, whether Nox1 is involved in the RV-mediated modulation of Akt 
signaling. This could be mediated by Rac, an important subunit for Nox1 activation which 
has been shown to be downregulated by RV in breast cancer cells206. To inhibit Nox1 
activation we applied a blocking peptide (gp91ds-tat) to the cells. The peptide consists of 
nine amino acids from p91phox that normally binds to p47phox. Originally, the peptide was 
designed to inhibit Nox2 assembling, but it was also shown to inhibit Nox2 homologues 
in the vascular system.172 With this p91phox docking sequence (ds) the blocking peptide 
inhibits the assembling of Nox1 with regulatory proteins by interfering with the p47phox 
binding by acting as decoy that binds p47phox180, 207. The tat-sequence is needed for import 
into the cells. As the recruitment of p47phox is important for the activation of Nox1 but 
not Nox4, the peptide could be used as a specifi c Nox1 inhibitor in VSMC169. As control, a 
nonsense peptide of the same length with a tat-sequence was used (gpco-tat).
Cells were pretreated with 50 μM RV, 100 μM gp91ds-tat or gpco-tat protein for 30 min, 
then stimulated as previously described with Ang II. Cells were lysed and phosphorylation 
of kinases was detected by western blot analysis. Gp91ds-tat-pretreatment led to an 
inhibition of Ang II-mediated Akt phosphorylation, while in control peptide-treated cells 
detected Akt phosphorylation was not infl uenced (Fig. 17A-B). In contrast to RV, gp91ds-
tat peptide inhibited p38 phosphorylation signifi cantly by more that 50 % (Fig. 17C) 
but phosphorylation of ERK only showed at slight but not signifi cant trend of reduction 
(Fig. 17D). The control peptide did not infl uence the phosphorylation of Akt, p38 and ERK 
(Fig. 17A). 
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Figure 17: Nox1 inhibition blunts the phosphorylation of Akt and p38 induced by 
Ang II
Quiescent VSMC were pre-treated with 100 μM gp 91 blocking peptide or control peptide, 
50 μM RV or vehicle control for 30 min, then stimulated with 100 nM Ang II for 10 min. 
Western blot analysis was performed, one representative blot is shown (A). Graphs represent 
mean densitometric signal of three independent experiments staining pAkt (B), pp38 (C), 
pERK (D). Ang II stimulation is set to 100 % (**, p < 0.01;*, p < 0.05; ns, not signifi cant; 
one-way ANOVA versus Ang II-treatment).
3.2.2.2. Nox1 inhibition does not alter the response of kinase phosphorylation upon   
  EGF stimulation
We then aimed to clarify the dependence of the signaling downstream of the EGF-R on Nox1 
in our cell system. Cells were incubated with RV, gp91ds-tat peptide or control peptide for 
30 min, and then activated with 100 ng/ml EGF for 5 min. Subsequently the phosphorylation 
of Akt, p38 and ERK was detected by western blotting. In contrast to stimulation with 
Ang II, EGF-induced phosphorylation of all tested kinases was not signifi cantly infl uenced 
by Nox1 inhibition, although graphs might show a tendency of kinase inhibition especially 
regarding p38 and ERK1/2 (Fig. 18A-D). Again, the control peptide did not inhibit any 
kinase phosphorylation signifi cantly. This proofs an involvement of Nox1 for the Ang II 
signaling but indicated that downstream of the EGF-R no Nox1 or Nox4 activity is necessary 
for activation of Akt, p38 and ERK. 
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Figure 18: Phosphorylation of Akt, p38 and ERK after EGF stimulation is independent 
of Nox1
Incubation of quiescent cells with 100 μM gp 91 blocking peptide or gp co control peptide, 
50 μM RV or vehicle control for 30 min was followed by treatment with 100 ng/ml EGF 
for 5 min. Protein amount was detected by western blot analysis. For each kinase one 
representative blot is shown. Mean protein levels measured by densitometric analysis of 
three individual experiments are shown. Data were normalized setting EGF stimulation to 
100 % (*, p < 0.05; ns, not signifi cant; one-way ANOVA versus EGF-treatment).
3.2.2.3. Nox inhibitor AEBSF inhibits ROS production after Ang II stimulation but   
  not Akt phosphorylation
To further verify whether the inhibition of Akt phosphorylation could be due to inhibition of 
Noxes by RV, we used as an alternative Nox blocker208. AEBSF is a serine protease inhibitor 
that blocks the recruitment of p47phox to the Noxes enzymes172 and can be therefore used 
as Nox1 inhibitor. 
Cells were treated with AEBSF for 30 min, then loaded with 20 μM H2DCF-DA and 
subsequently stimulated with Ang II for 15 min. Intracellular ROS was measured by 
fl ow cytometry. We found that 100 μM AEBSF inhibited intracellular ROS signifi cantly 
(Fig. 19). 
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Figure 19: AEBSF treatment decreases in-
tracellular ROS after Ang II stimulation
Serum-starved VSMC were preincubated for 
30 min with AEBSF (50 μM, 100 μM, 200 μM), 
incubated 15 min with 20 μM H2DCF-DA in 
HBSS buffer and then cells were stimulated 
with 100 nM Ang II for 15 min. Using fl ow 
cytometry intracellular ROS was measured. 
Graphs show average fl uorescent signal from 
three independent experiments. Ang II stimula-
tion was set to 1, (*, p < 0.05; one-way ANOVA 
versus Ang II-treatment).
Next we asked if AEBSF can impede the phosphorylation of Akt similar to RV. Treatment 
of VSMC with 10-200 μM AEBSF for 30 min as used in mouse fi broblasts209 or 2 h before 
stimulation with Ang II for 10 min showed, that it was not able to block the Akt signal 
(Fig. 20A), although 100 μM were able to abolish ROS induction (Fig.19). Treating the 
cells with up to 1 mM AEBSF as used in mesengial cells210, the phosphorylation of Akt 
was even activated, whereas p38 and ERK phosphorylation were inhibited at these high 
concentrations (Fig. 20B-C). Taken together these data show an effect of AEBSF infl uencing 
Ang II-induced ROS in our cell system, whereas its infl uence on the phosphorylation of 
Akt, p38 and ERK1/2 are contrarious as higher dosage increased Akt phosphorylation but 
seemed to inhibit phosphorylation of p38 and ERK.
3.3. Inhibition of Ang II- but not EGF-induced phosphorylation of Akt by 
DPI and NAC
It was previously demonstrated that the inhibitory effect of RV on VSMC hypertrophy is 
mediated mainly by interfering with phosphorylation of Akt42 whereas other MAPK (p38/
ERK1/2) remain largely unaffected. Our previous experiments indicated at role of Nox1 for 
Ang II-induced Akt phosphorylation but neither Nox1 nor Nox4 seemed to be important 
for the EGF-mediated signaling. To clarify the dependence of Ang II or EGF stimulation 
on ROS in our cells we applied two antioxidative substances, the fl avoprotein inhibitor DPI 
and a general antioxidant and precursor of glutathione N-acetyl cysteine (NAC), on the 
cells.
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Figure 20: AEBSF has no infl uence on Ang II-induced phosphorylation of Akt
Quiescent cells were loaded with 10 - 1000 μM AEBSF for 30 min or 2 h and activated 
with 100 nM Ang II for 10 min followed by western blot analysis using antibodies against 
pAkt (A), pp38 (B), pERK1/2 (C) and tubulin as loading control. Graphs show the mean 
densitometric signals of pAkt (A), pp38 (B) and pERK1/2 (C) antibodies detected after 
30 min AEBSF preincubation time. One representative blot is shown for pAkt (A) with 
AEBSF pretreatment for 30 min or 2 h. Graphs represent densitometric signal, measured in 
one to three experiments, Ang II stimulated cells were set to 1.
We pretreated VSMC with 10 μM DPI for 1 h or 10 mM NAC for 2 h and cell lysates were 
subjected to Western blot analysis using antibodies against phospho-Akt, phospho-p38, 
and phospho-ERK and for normalization against tubulin. Blocking of Akt phosphorylation 
after Ang II stimulation with DPI and NAC was already shown in VSMC.211 We found 
that Ang II (100 nM, 10 min) induced phosphorylation of Akt was blocked by NAC pre-
incubation (Fig. 21A) as effective as with RV while DPI inhibited Akt phosphorylation was 
less effi cient. Phosphorylation of Akt upon EGF stimulation (100 ng/ml, 5 min) could only 
be selectively inhibited by RV pretreatment. NAC and DPI preincubation did not interfere 
with phosphorylation of Akt when induced by EGF stimulation (Fig. 21B). RV had no effect 
on the phosphorylation of p38 after Ang II stimulation whereas NAC and DPI were able 
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Figure 21: Antioxidants inhibit Ang II-induced phosphorylation of Akt, p38 and ERK
Serum-deprived cells were pretreated with 50 μM RV or DMSO for 30 min, 10 μM DPI for 
1 h or 10 mM NAC for 2 h, then stimulated with 100 nM Ang II for 10 min and lysates were 
subjected to western blot analysis using antibodies to pAkt (A-B), pp38 (C-D) and pERK1/2 
(E-F). Tubulin served as loading control. For each antibody one representative blot is shown, 
graphs represent densitometric signal obtained by three independent experiments. Ang II 
or EGF stimulation was set to 100 % (**, p < 0.01;*, p < 0.05; ns, not signifi cant; one-way 
ANOVA versus Ang II-or EGF-treatment).
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to block the phosphorylation to basal levels (Fig. 21C). In contrast both antioxidants had 
no effect on p38 phosphorylation after EGF stimulation (Fig. 21D). Phosphorylation of the 
MAPK ERK1/2 was not signifi cantly inhibited by RV pretreatment after Ang II stimulation, 
only NAC could block Ang II-induced ERK 1/2 phosphorylation by about 50 % (Fig. 21E). 
In the EGF stimulated cells no effect of NAC or DPI on the phosphorylation of ERK1/2 
could be detected (Fig. 21F). These results indicate that antioxidants such as NAC and DPI 
can mimic the effect of RV on Ang II-mediated pAkt, but not on EGF-mediated pAkt.
3.4. Effects of additional antioxidants on VSMC
We showed before that phosphorylation of different kinases upon stimulation with Ang II 
could be blocked by two different general antioxidative active compounds in VSMC and is 
most likely redox dependent. To verify these results, other known redox-active compounds 
with a more selective mode of action were tested in a similar experiment-setup.
3.4.1. Hydroxyl radical scavengers do not interfere with phosphorylation of Akt in 
VSMC
Two potential membrane crossing hydroxyl radical (OH•) scavengers 
N-(2-mercaptopropionyl)-glycine (N-MPG) and dimethyl thiourea (DMTU) were tested 
whether they could infl uence the Ang II-induced Akt signaling in VSMC as RV does. MPG 
is cell-permeable and a powerful scavenger of OH•.212 DMTU is highly diffusible, has a 
long half-life and high potency in scavenging hydrogen peroxide (H2O2) and OH
•.213, 214 
VSMC were preincubated with 50 μM to 10 mM DMTU for 30 min or 2 h before 
stimulation with Ang II as previously described. DMTU pretreatment did not affect the Akt, 
p38 or ERK1/2 phosphorylation induced by Ang II (Fig. 22A). Pretreatment of cells with 
50 – 300 μM MPG for 30 min (Fig. 22B) showed a slight inhibition of phosphorylation of 
Akt and p38 after Ang II stimulation detected by western blot analysis. But as this effect 
was not always reproducible and therefore not statistically signifi cant when repeating the 
experiments several times we did not pursuit this effect any longer.
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Figure 22: Hydroxyl scavengers cannot inhibit Akt phosphorylation in Ang II-activated 
VSMC
Serum-deprived VSMC were pretreated with 50 μM - 10 mM DMTU (A) or 50 to 300 μM 
MPG (B) for 30 min or 2 h, and then stimulated with 100 nM Ang II for 10 min. Proteins 
were subjected to western blot analysis using antibodies to pAkt, p38 and pERK1/2 as well 
as tubulin as loading control. One representative blot is shown from one to three individual 
experiments.
3.4.2. No effect of SOD and catalase mimetics on phosphorylation of Akt
Two main intracellular defence mechanisms against ROS are superoxide dismutase (SOD) 
and catalase. SOD dismutates O2
•- to H2O2 and catalase is catalysing the reaction of H2O2 
to water. 161, 162 Beside inhibition of Noxes RV could also decrease ROS by detoxifying 
it a way similar to SOD and catalase action in the cells. Therefore two SOD and catalse 
mimicking compounds were tested in VMSC. EUK 134 and Mn(III)terakis(1-methyl-
4-pyridyl)porphyrin pentachloride (MnIIITM), both manganese-porphyrins, were used 
with 30 min or 2 h preincubation time in concentrations of 50-200 μM, according to the 
literature.215,216 When cells were stimulated with Ang II neither of these two compounds was 
able to interfere with the Akt phosphorylation detected by immunoblotting (Fig. 23 A-B). 
These data indicate that selective inhibition of O2
•-, H2O2, and OH• formation cannot lead 
to inhibition of phosphorylation of Akt upon Ang II stimulation, and that it is therefore 
unlikely that RV interferes with phosphorylation of Akt by detoxifi cation of a specifi c form 
of reactive oxygen species.
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Figure 23: Phosphorylation of Akt is not impeded by SOD and Catalase mimetics in 
VSMC.
Serum-starved cells were loaded with 50 - 200 μM MnIIITM (A) or 50 - 200 μM EUK (B) 
for 30 min or 2 h. Phosphorylation of proteins was detected by western blot analysis after 
stimulation with 100 nM Ang II for 10 min, tubulin served as loading control. One blot for 
each kinase (pAkt, pp38, and pERK1/2) is shown; the top panel represents signals obtained 
after 30 min preincubation time, the bottom panel shows signals after 2 h pretreatment with 
MnIIITM and EUK. The experiment was performed one to three times.
Due to unconvincing effects of the other antioxidative compounds on Akt phosphorylation 
after Ang II stimulation we did not include additional experiments using EGF as activator 
of Akt phosphorylation.
3.5. Oxidation of Shp2 after Ang II and EGF treatment
The thiol groups of cysteins in protein tyrosine phosphatases (PTPs) are very important 
for their action217 and are also target of oxidation leading to inactivation of PTP.132, 218 
Shp2, a PTP, plays a pivotal role in Akt and ERK signaling, negatively infl uencing Akt 
and activating ERK154. A recent publication indicated that Shp2 is redox-regulated by Ang 
II149. Shp2 was shown to be activated by RV44, possibly by interfering with Ang II- or 
EGF-mediated oxidation of Shp2. In order to test a redox-dependent effect of RV on Shp2 
we applied a specifi c assay to detect oxidized PTPs using an antibody directed against the 
sulfonic acid form of phosphatases198, 219.
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Figure 24: Oxidation of Shp2 after Ang II stimulation
After incubation of quiescent cells with 100 nM Ang II and 3 mM H2O2 for indicated times an 
IP of Shp2 was performed. One half of the samples were treated with IAA to protect reduced 
(active) forms of Shp2, the other half was used without IAA (positive control). Protein levels 
were detected by western blot analysis, using an anti-oxidized PTP and Shp2 antibody. The 
graph represents the ratio of oxidized PTP in IAA treated cells and positive control cells 
(without IAA), related to the total Shp2 amount after IP (A). One representative blot out of 
three individual experiments is shown (B).
Cells were stimulated with 100 nM Ang II for different times, and Shp2 oxidation was 
measured with the oxidized PTP-assay as described in the part Materials and Methods. 
H2O2 was used as positive control. A ratio of the amount of oxidized PTP with IAA to 
protect reduced (active) forms of Shp2 and without IAA (positive control) was calculated, 
and related to the total Shp2 amount. Interestingly, Shp2 was already oxidized in untreated 
samples, indicating a high basal oxidation level of Shp2. As shown in the graph and also 
in the representative blots no further oxidation of Shp2 was detectable within 10 min 
treatment with Ang II. Even the positive control (3 mM H2O2, 10 min) did not lead to a 
higher oxidation percentage of oxidized Shp2 compared to the control (Fig. 24A-B). When 
applying the same assay in cells pretreated with RV (50 μM, 30 min) or 0.1 % DMSO and 
then stimulated with Ang II (100 nM, 10 min) or EGF (100 ng/ml, 5 min) no induction 
in oxidation could be seen after Ang II (Fig. 25A) or EGF (Fig. 25B) stimulation or RV 
pretreatment.
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Figure 26: Non-redox active derivatives of RV
In contrast to RV, which possesses three phenolic groups the derivative Tri-O-methylresveratrol 
(TM-RV) has all three hydroxyl groups methylated (A), the derivative 3,5-Dihydroxy-4’-
methylstilben (R1) is methylated at the 4´OH (B).
Synthesized by the group of Prof. Erker (Department of Pharmaceutical Chemistry, Uni. of 
Vienna)
OCH3
OH
OH
R1
3,5-Dihydroxy-4'-methylstilben
O
O
O
trans-3,4',5-Trimethoxystilbene
Tri-O-methylresveratrol 
CH3
CH3
CH3
A B
3.6 Effect of redox-inactive derivatives of RV on Akt activation
To further clarify the role of RV as a redox-active compound when inhibiting Akt 
phosphorylation in our cell system we applied two redox-inactive derivatives of RV, Tri-O-
methylresveratrol (TM-RV), with all three hydroxyl groups methylated (Fig. 26A), and 3,5-
Dihydroxy-4´-methylstilben (R1), methylated at the 4´OH (Fig. 26B). The phenol groups 
at the 3, 4´or 5-position, particularly the 4´OH, was shown to be important for the depletion 
of ROS by RV.27-29 
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Figure 25: Shp2 oxidation after RV pre-treatment and Ang II or EGF stimulation
Serum-starved cells were stimulated with 100 nM Ang II for 10 min or 100 ng/ml EGF 
for 5 min after preincubation with 50 μM RV for 30 min or 0.1 % DMSO. 3 mM H2O2 
stimulation of the cells for 10 min served as positive control. Shp2 was immunoprecipitated, 
using IAA in one half of the samples and for positive control IAA in the other half. Protein 
levels were detected by western blot analysis, using an anti-oxidized PTP antibody and a 
Shp2 antibody. The experiment was carried out one to two times; one representative blot per 
stimulation is shown.
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Neither of the two derivatives was found to signifi cantly reduce H2O2 levels as RV did 
(Experiment performed by Julia Gesslbauer, diploma student; data not shown).
We therefore pretreated the cells with the derivatives TM-RV and R1 (50 μM, 30 min) 
and as positive control with RV (50 μM, 30 min) and then stimulated the cells with Ang II 
(Fig. 27A) or EGF (Fig. 27B) as previously described. TM-RV inhibited neither the Ang  II 
nor EGF induced Akt phosphorylation. Interestingly, the derivative R1, which has been 
shown not to be redox active, reduced phosphorylation of Akt after Ang II treatment by 
over 50 %, to a level comparable to RV-mediated inhibition. EGF-induced phosphorylation 
of Akt was even inhibited equally well by R1 compared to the effect of RV. This data clearly 
shows that RV can inhibit Akt phosphorylation even without antioxidative properties in 
both Ang II and EGF stimulated VSMC. The 4´phenolic group hereby seems not to play a 
pivotal role. 
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Figure 27: Non-redox active derivatives of RV can inhibit the phosphorylation of Akt 
after Ang II and EGF stimulation
Serum-deprived cells were pretreated with RV or RV derivatives TM-RV and R1 for 30 min, 
followed by stimulation with 100 nM Ang II for 10 min (A) or 100 ng/ml EGF for 5 min 
(B). Protein levels were detected by western blot, one representative blot per stimulation 
is shown. Graph represents mean densitometric signal of three independent experiments. 
Ang II or EGF stimulation is set to 100 % (**, p < 0.01 one-way ANOVA versus Ang II- or 
EGF-treatment).
This experiment was performed by Julia Gesslbauer (diploma student in our group).
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Figure 28: Difference in the phosphorylation of 
Shp2 upon Ang II or EGF treatment
Shp2 phosphorylation at Tyr542 was detected in qui-
escent cells which were loaded with 50 μM RV or 
vehicle control for 30 min, then treated with 100 nM 
Ang II (10 min) or 100 ng/ml EGF (5 min). Follow-
ing western blotting, the band intensities were den-
sitometrically analyzed, the graph shows the mean 
of three independent experiments. One representa-
tive blot is shown for pShp2, total Shp2 and tubulin. 
Data were normalized using Ang II stimulation as 
100 % (**, p < 0.01, ns, not signifi cant; t-test).
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4. Redox-unrelated mechanisms of RV infl uencing Shp2
4.1. Phosphorylation of Shp2
4.1.1. Shp2 phosphorylation at Tyr542 in response to Ang II or EGF stimulation
Beside redox regulation of Shp2 it was shown to be activated via phosphorylation of 
tyrosine-residues131, 140. In a non-active Shp2 the N-terminal SH2 domain and the catalytic 
domain interact, rendering a low basal activity. Shp2 can be activated either by binding 
phosphorylated tyrosines of binding proteins, such as Gab1, with the two SH2 domains 
or by phosphorylation of the two tyrosine residues (Tyr542, Tyr580) at the C-terminus of 
Shp2.131, 140 An induction of phosphorylation of Shp2 after Ang II stimulation was reported 
recently149, therefore we checked the phosphorylation status of Shp2 after Ang II and EGF 
treatment at Tyr542.
Cells were stimulated with 100 nM Ang II for 10 min or 100 ng/ml EGF for 5 min 
after pretreating them with RV or vehicle control for 30 min. The western blot analysis 
using an antibody against phospho-Tyr542-Shp2 revealed that after Ang II stimulation 
the phosphorylation of this tyrosine residue is induced signifi cantly by more than 
60 %. Pretreatment with RV even enhanced this phosphorylation for additional 20 %. 
Interestingly, upon EGF treatment or RV preincubation followed by EGF stimulation the 
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Shp2 phosphorylation did not increase signifi cantly (Fig. 28). According to these results we 
conclude that the phosphorylation of Shp2 is differently regulated and modulated by RV in 
Ang II and EGF signaling pathways.
4.1.2. Antioxidant treatment can not reduce the phosphorylation of Shp2
The Ang II stimulation in VSMC is leading to a transactivation of the EGF-R and Nox1 
plays an important role for the signal transduction165. ROS production was already shown 
to induce the phosphorylation and activity of Shp2149. Due to this we examined whether the 
enhanced phosphorylation of Shp2 after Ang II stimulation is also redox regulated in our 
cell system. Cells were incubated with 50 μM RV, 0.1 % DMSO (30 min), 10 μM DPI (1 h) 
or 10 mM NAC (2 h) followed by stimulation with Ang II (100 nM, 10 min). We found that 
the phosphorylation of Shp2 was not reduced signifi cantly by NAC or DPI preincubation 
followed by Ang II activation. Compared to RV treatment, NAC led to a statistically 
signifi cant downregulation of Shp2 phosphorylation, suggesting that RV infl uences the 
phosphorylation of Shp2 not mainly via a redox-dependent mechanism (Fig. 29).
Figure 29: Infl uence of antioxidants on Shp2 
phosphorylation
After pre-treatment of serum-starved cells with 
50 μM RV or 0.1 % DMSO for 30 min, incuba-
tion with 10 μM DPI (1h) or 10 mM NAC (2h), 
cells were stimulated with 100 nM Ang II for 
10 min. Proteins were subjected to western blot 
analysis for pShp2 and tubulin (loading control). 
Graphs represent mean densitometric signals from 
four independent experiments. Ang II stimulation 
is set to 100 % (**, p < 0.01; *, p < 0.05; ns, not 
signifi cant; t-test).
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Figure 30: EGFR-kinase activity is not important for 
the phosphorylation of Shp2 after Ang II stimulation
Phosphorylation of Shp2 was detected by western blot-
ting after incubation of quiescent VSMC with 250 nM 
AG1478 and 50 μM RV or vehicle control for 30 min, 
followed by stimulation with Ang II (100 nM, 10 min). 
Graphs represent the mean densitometric signal of two 
to four independent experiments. Data were normalized 
setting Ang II stimulation to 100 % (ns, not signifi cant; 
one-way ANOVA versus Ang II-treatment).
4.1.3. Phosphorylation of Shp2 in response to Ang II stimulation occurs mainly   
 independent of the EGF-R
Prior to regulation of ERK1/2 signaling220 and PI3K activity after EGF stimulation Shp2 is 
recruited to the EGF-R154. Elucidating the disparate regulation of the phosphorylation of Shp2 
after Ang II and EGF stimulation (Fig. 29) strongly argues for an EGF-R and thus EGF-R 
transactivation-independent way of Shp2 phosphorylation upon Ang II stimulation.
To test this hypothesis cells were pretreated with an EGF-R-kinase inhibitor, AG1478 
(250 nM, 30 min) and stimulated with Ang II (100 nM, 10 min). As shown in the graph 
the phosphorylation of Shp2 upon Ang II stimulation could not be abolished with AG1478 
treatment (Fig. 30). This result suggests that, beside the EGF-R transactivation, Ang II acts 
on Shp2 via a different, parallel pathway.
4.2. Ang II-induced phosphorylation of Akt, p38 and ERK1/2 are   
 partly independent of EGF-R kinase activity
To clarify whether the signal from the AT1R towards Akt, ERK1/2 and p38 phosphorylation 
require the transactivation of the EGF-R we activated cells with Ang II and blocked the 
EGF-R with the EGF-R-kinase inhibitor AG1478. VSMC were treated with AG1478 
(250  M, 30 min) or 50 μM RV (30 min) and then stimulated with 100 nM Ang II for 10 min. 
Western blot analysis showed that Akt and p38 phosphorylation after Ang II stimulation 
was reduced to 50 % by AG1478 (Fig. 31A-B) and the phosphorylation of ERK was even 
blunted to 30 % in the presence of AG1478 (Fig. 31C). But still a phosphorylation of 
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Figure 31: Phosphorylation of Akt, p38 and ERK is 
partially infl uenced by AG1478 upon Ang II treat-
ment 
Serum-starved VSMC were incubated with 250 nM 
AG1478 and 50 μM RV or 0.1 % DMSO for 30 min 
followed by stimulation with Ang II (100 nM, 10 min). 
Cells were lysed and western blotting was performed 
for protein detection using antibodies against pAkt 
(A), pp38 (B) and pERK1/2 (C). Graphs represent the 
mean signal of three individual experiments measured 
by densitometric analysis. Ang II stimulation is set 
to 100 % (**, p < 0.01;*, p < 0.05; one-way ANOVA 
versus Ang II-treatment). 
all three kinases could be seen after Ang II stimulation. The effect of AG1478 was not 
comparable to the RV-mediated inhibition as this acts selectively on Akt phosphorylation 
but does not block ERK1/2 or p38 phosphorylation. 
As control for the effectiveness of the inhibitor, cells were stimulated with 100 ng/ml EGF 
for 5 min after 30 min pretreatment with 250 nM AG1478 or 50 μM RV. Phosphorylation 
of Akt, p38 and ERK was detected by Western blot analysis using specifi c antibodies. As 
expected, AG1478 pretreatment led to a total inhibition of phosphorylation of the three 
kinases to basal level. RV only blocked the phosphorylation of Akt, but did not infl uence 
ERK or p38 activation signifi cantly (Fig. 32A-C). These data support the idea that in VSMC 
20 - 50 % of the Ang II-induced signal for Akt, p38 and ERK are transduced independently 
of the EGF-R. Furthermore, they show that the EGF-R kinase activity is absolutely required 
for EGF-induced Akt, p38 and ERK1/2 signaling in VSMC. 
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4.3. Recruitment of PI3K to Shp2
Shp2 was shown to regulate PI3K binding to Gab1, which is needed for activation of the 
Akt pathway in fi broblasts in response to EGF stimulation.154 Therefore we examined a 
possible interaction of Shp2 and PI3K in VSMC upon stimulation. To further elucidate the 
role of PI3K in our system we performed an IP of Shp2 after Ang II or EGF stimulation 
and RV pretreatment and analyzed the co-precipitation of p85, the regulatory subunit of 
PI3K, with a specifi c antibody. As Fig. 33 shows, no p85 recruitment to Shp2 could be 
detected after Ang II treatment. In contrast, EGF stimulation led to a signifi cant increase of 
PI3K-Shp2 interaction, arguing for a co-localization in a “Shp2-PI3K-signaling complex” 
of both. This indicates that PI3K is differently regulated in Ang II and EGF signaling and 
might play a distinct role. RV pretreatment does not change the recruitment after Ang II- or 
EGF-mediated activation of the cells. 
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Figure 32: AG1478 treatment totally diminishes the 
phosphorylation of Akt, p38 and ERK after EGF 
stimulation
After pretreatment of serum-deprived cells with 
AG1478 (250 nM, 30 min) or 50 μM RV or vehicle 
control (30 min), they were stimulated with EGF 
(100 ng/ml, 5 min). Protein levels of pAkt (A), pp38 
(B) and pERK1/2 (C) were detected by western blot 
analysis. Three independent experiments are summed 
up in the graphs, showing mean band intensities. Data 
were normalized setting EGF stimulation to 100 % (**, 
p < 0.01;*, p < 0.05; one-way ANOVA versus EGF-
treatment).
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Figure 33: Differences in PI3K recruitment to Shp2 
after Ang II and EGF stimulation
After pre-treatment with RV (50 μM, 30 min) or vehicle 
control quiescent cells were stimulated with 100 nM 
Ang II (10 min) or 100 ng/ml EGF (5 min). After lysis 
of the cells an IP of Shp2 was performed and proteins 
co-precipitated were detected by western blotting. A 
representative blot is shown for p85 and Shp2. Graph 
shows mean densitometric signal of three individual ex-
periments, related to total Shp2 amount after IP. Ang II 
stimulation was set to 100 % (**, p < 0.01;*, p < 0.05; 
ns, not signifi cant; t-test). 
4.4. Shp2 knock down
As the previous data indicate a different role for Shp2 in the EGF and Ang II signaling we 
wanted to clarify its importance for the signaling and also examine whether it is the main 
target of RV. Therefore we treated the cells with 50 μM Shp2 siRNA for 72 h, added RV 
for 30 min and stimulated the cells with Ang II and EGF. Protein levels were analyzed by 
western blotting and densitometric analysis. The Shp2 levels in VSMC were reduced to 
50 % compared to scrambled siRNA treated cells. Comparing the siRNA treated cells with 
the scrambled control cells neither the induction of Akt phosphorylation by Ang II or EGF 
nor the RV-mediated inhibition of phospho Akt was signifi cantly infl uenced by the changed 
Shp2 protein level (Fig. 34A-B).
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Figure 34: No infl uence of 50 % Shp2 knock down on Ang II- or EGF-stimulated Akt 
signaling and RV-mediated inhibition of phospho Akt
Serum-starved cells were treated with 50 μM siRNA for Shp2 or 50 μM scrambled control 
siRNA followed by incubation with RV or vehicle control for 30 min. Then cells were 
stimulated with 100 nM Ang II, 10 min (A) or 100 ng/ml EGF, 5 min (B). Protein levels were 
detected by performing western blotting and subsequently densitometric analysis of bands. A 
representative blot is shown for pAkt, total Shp2 and tubulin. Four independent experiments 
are summarized in the graphs, showing the mean band intensities. Data were normalized 
using Ang II or EGF stimulation of scrambled control as 100 % (**, p < 0.01; t-test).
5. Additional potential mechanisms of RV
5.1. Kinetics of RV-mediated inhibition of Ang II and EGF-induced   
 phosphorylation of Akt 
The inhibition of Akt phosphorylation by RV was always shown after a preincubation time of 
30 min (Fig. 11). To shed more light on the mode of action of RV we tested whether RV can 
also inhibit Akt phosphorylation when applied after Ang II or EGF stimulation. Cells were 
stimulated with either 100 nM Ang II or 100 ng/ml EGF and RV was added up to 10 min 
after the stimulation (Fig. 35A-B). Surprisingly, addition of RV even 7 or 9 min after Ang II 
still led to a signifi cant inhibition of the phosphorylation of Akt by ~ 40 %. Inhibition of Akt 
phosphorylation by RV was below 50 % when added up to 7 min after Ang II. Application 
of RV 5 to 7 min after Ang II stimulation resulted in higher inhibition rates, and when added 
within 2 min after Ang II phospho-Akt levels were comparable to prestimulation with RV. 
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Figure 35: RV treatment after Ang II- and EGF stimulation inhibits phosphorylation 
of Akt
Serum-starved cells stimulated with 100 nM Ang II (A) for 10 min or 100 ng/ml of EGF for 
5 min (B) were treated with 50 μM RV for indicated the times. Lysates were subjected to 
western blot analysis using antibodies to pAkt and tubulin (loading control). 0.1 % DMSO 
was used as vehicle control. One representative blot is shown; graphs represent signal intensity 
detected by densitometric analysis of three to four immunoblots. Ang II or EGF stimulation, 
respectively, was set to 100 % (**, p < 0.01; ns, not signifi cant; one-way ANOVA versus 
Ang II-or EGF-treatment).
Stimulating cells with EGF, RV inhibited phosphorylation of Akt when added within 4 min 
after EGF-application. Addition of RV up to 3 min after stimulation with EGF blocked the 
Akt phosphorylation to nearly the same extent like RV preincubation. 
5.2. PI3K as target
To get more ideas about the mode of action of resveratrol we examined different stimuli next 
to Ang II and EGF which are all activating Akt via PI3K. PI3K is an important modulator 
downstream of the EGF-R, binding to Gab1 and leading to Akt phosphorylation83. RV 
was previously shown to inhibit PI3K activity221, which could explain the inhibition of 
phosphorylation of Akt after stimulation with Ang II and EGF. 
We therefore used insulin, a potent stimulus of PI3K110, and investigated whether RV can 
also inhibit insulin-mediated Akt phosphorylation. A 10 or 30 min incubation of VSMC with 
100 nM insulin led to a 3-fold increase in the phosphorylation of Akt, comparable to Ang II 
stimulation (Fig. 36). RV completely blocked this phosphorylation reducing phospho-Akt-
levels even below basal levels, similar to the effect on Ang II stimulated cells. 
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Figure 36: Insulin induced phosphorylation of 
Akt in VSMC
Quiescent cells were stimulated with 100 nM In-
sulin for 10 min or 30 min. Protein detection was 
performed by immunoblotting and mean intensity 
measured by densitometric analysis of three individ-
ual experiments is shown for pAkt. One represen-
tative blots is shown. Insulin stimulation was set to 
100 % (**, p < 0.01; ns, not signifi cant; t-test). - +
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Figure 37: RV and WM block phosphorylation of 
Akt in VSMC
Serum-starved VSMC were stimulated with 100 nM 
Insulin for 10 min after preincubation with 50 μM 
RV, 0.1 % DMSO or 50 nM WM for 30 min. Western 
blotting was used for protein detection and mean of 
densitometric analysis is shown. One out of three rep-
resentative blots is shown for pAkt and tubulin. Data 
were normalized using Insulin stimulation as 100 % 
(**, p < 0.01; one-way ANOVA versus Insulin-treat-
ment). 
We next compared the inhibition of Akt phosphorylation to the effect of Wortmannin 
(WM), a potent PI3K inhibitor. Cells were stimulated with 100 nM Insulin for 10 min after 
a 30 min preincubation with 50 μM RV or 50 nM WM. The detection of the protein levels 
with western blotting revealed that RV can block the insulin induced phosphorylation of 
Akt nearly as powerful as WM (Fig. 37). Since RV turned out to inhibit phosphorylation of 
Akt upon various stimuli (Ang II, EGF, Insulin) and PI3K is upstream of pAkt, PI3K may 
constitute a target of RV in VSMC.
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Figure 38: Sirtinol does not infl uence the RV-mediated inhibition of phosphorylation of 
Akt in VSMC
Sirtinol (10 μM, 15 min) pretreated serum-deprived cells were incubated with RV (50 μM) 
for 30 min before stimulation or stimulated directly with Ang II (100 nM, 10 min) (A) or EGF 
(100 ng/ml, 5 min) (B). 0.1 % DMSO for 30 min was used as vehicle control. Cell lysates 
were subjected to immunoblotting using antibodies to pAkt and tubulin. Protein detection 
was performed by measuring densitometric analysis. One representative blot is shown. 
Graphs show mean of densitometric analysis of three independent experiments. Data were 
normalized using Ang II or EGF-stimulation as 100 % (**, p < 0.01;*, p < 0.05; t-test).
5.3. Sirtuins as target of RV
An in vitro screening identifi ed RV as a potent inducer of the of huSIRT1 deacetylase activity.35 
Many different effects of RV were found to be due to activation of sirtuins33, therefore we 
applied Sirtinol, a potent SIRT1 inhibitor effective at low concentrations222 to test whether 
the RV effect of Ang II- and EGF-mediated signaling is also SIRT1-dependent. Cells were 
treated with 10 μM Sirtinol for 15 min or RV (50 μM, 30 min), followed by stimulation 
of the cells with Ang II (100 nM, 10 min) or EGF (100 ng/ml, 5 min). Pretreatment of the 
cells with Sirtinol did not abolish inhibitory effect of RV on the phosphorylation of Akt, 
while preincubation of the cells with Sirtinol alone also did not infl uence the Ang II- or 
EGF-induced phosphorylation of Akt (Fig. 38A-B). Referring to these results we exclude an 
involvement of sirtuins in the repression of Akt phosphorylation by RV in the VSMC.

E   DISCUSSION
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It has previously been shown by our group that RV can inhibit Ang II-induced hypertrophy 
in VSMC by interfering with the Akt/PI3K pathway. Further it was suggested that RV 
blocks Akt activation after Ang II- or EGF stimulation by activating Shp2, thus interfering 
with the interaction of Gab1 and PI3K that is necessary for the signaling to Akt42-44. In 
this study we tested whether this effect of RV is due to its antioxidative properties by 
infl uencing the redox-sensitive phosphatase Shp2 and/or NADPH oxidases downstream of 
the EGF-R as previous data showed that the EGF-R transactivation is not infl uenced by RV. 
The study showed that although RV could inhibit intracellular and extracellular ROS, the 
phosphorylation of Akt is redox-independent downstream of the EGF-R in VSMC. Nox1 
was shown to be responsible for the Akt, p38 and ERK1/2 phosphorylation after Ang II 
stimulation which is in accordance with the literature. EGF- induced Akt, p38 and ERK1/2 
phosphorylation in contrast was Nox1 independent. We also found that Nox4 is not involved 
in Ang II- or EGF-induced Akt and MAPK (p38/ERK1/2) phosphorylation. Using redox 
inactive derivatives of RV in this setting underlined that antioxidative properties of RV 
are not necessary for the inhibition of Akt phosphorylation. In addition we could not fi nd 
evidence for a redox regulation of Shp2 using oxPTP antibodies, but detected differences 
in the phosphorylation of Shp2 and in PI3K recruitment to Shp2 upon stimulation of cells 
with Ang II or EGF. Our fi ndings therefore have led to a more complete understanding and 
of the mode of action of RV against VSMC hypertrophy by excluding an antioxidative 
effect of RV.
1. Antioxidative effect of Resveratrol
RV, like other polyphenols, is known for its antioxidative effect200 and it was suggested to 
inhibit Ang II and EGF-mediated Akt phosphorylation possibly by interfering with ROS 
production downstream of the EGF-R . In this study we could show for the fi rst time that 
RV also acts as an antioxidant in rat VSMC. RV was able to inhibit Ang II-induced ROS 
levels in our cell system, and led to reduced basal intracellular ROS levels, which were 
comparable to those upon administration of the fl avoprotein inhibitor DPI. Similar data 
regarding inhibition of ROS production by RV was obtained in cardiomyocytes45, in human 
aortic VSMC (inhibition of PDGF-induced ROS)223, and in bovine smooth muscles cells 
(inhibition of oxLDL induced ROS)224 as well as in various other cells systems9, 225. As EGF-R 
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phosphorylation was shown to be susceptible for modulation by ROS226 and the EGF-R was 
found to also generate H2O2 after stimulation of A431 human epidermoid carcinoma cells 
with EGF227, we looked if the H2O2 production in our cell system is triggered by EGF-R 
activation. However, we were not able to detect any intracellular ROS-increase after EGF 
stimulation, which could be due to a high basal cellular ROS level already present in 
unstimulated VSMC. Still, RV was able to reduce ROS below levels found in vehicle control 
treated cells, indicating an antioxidative role of RV. Further, extracellular ROS, which were 
enhanced by Ang II or EGF stimulation, were also brought down below basal levels by RV. 
The increase of extracellular ROS was in accordance with literature where extracellular 
H2O2 production is due to an activated EGF-R.
203 These antioxidative properties of RV are 
thought to include several mechanisms. RV was shown to directly scavenge ROS21, 228, and 
also to upregulate the expression of endogenous antioxidants such as SOD and catalase in 
SMC, with measurable effects 24 h after RV-addition25. In our experimental setting, RV 
already blunted ROS after a 30 min preincubation. Therefore, we can exclude the latter 
in our system, leaving direct ROS scavenging as a potential explanation for the strong 
effect of RV on intra- and extracellular ROS. Another possibility would be that RV acts on 
fl avoproteins (e.g. Noxes) like DPI which was shown to inhibit phosphorylation of Akt in 
VSMC211. 
1.1. Role of Noxes in Ang II- and EGF-induced signaling
Noxes, especially Nox1, seem to be important for the regulation of Ang II induced signaling 
as they are necessary for transactivation of the EGF-R.229 Further, Nox4 was found co-
localized with the activated EGF-R, indicating a role of both Noxes in Ang II and EGF 
signaling.181, 191 In cardiomyocytes Ang II was shown to induce O2
•- in a Nox2 and Rac1 
dependent way leading to Akt activation and hypertrophy.230 RV has already been reported 
as suppressor of Ang II-induced Nox activity in endothelial cells48 and it was shown to 
inhibit LPS-induced Nox1 expression in macrophages leading to inhibition of foam cell 
formation231. This all implicates an impact of RV in Nox regulation. In addition, a role of 
Nox 4 downstream of the EGF-R was proposed, as other groups found a Nox4-based but 
Rac-dependent ROS production in rat mesangial cells that was shown to be important for 
Ang II induced protein synthesis via Akt.189 Moreover, it was also shown before that the 
EGF-R is able to produce H2O2 upon stimulation
203, to co-localize with Nox4 in VSMC 
when activated181, and to inactivate PTP1B that is localized at the EGF-R in HAECs232.
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A lack of specifi c antibodies against Noxes made it impossible to detect Nox protein levels 
after siRNA treatment of the cells. 180, 233 Therefore mRNA levels were analyzed to test 
for suffi cient Nox4 reduction. Stimulation of cells, that have been depleted of Nox4 by a 
specifi c siRNA, with Ang II or EGF, did not lead to a difference in the phosphorylation of 
Akt, p38 or ERK when compared to nonsense RNA-treated and stimulated cells. Also no 
changes in the RV-caused inhibition of phosphorylated Akt were seen upon treatment with 
Nox4 siRNA. Therefore we could rule out that Nox4 plays a pivotal role in Ang II or EGF 
signaling and that RV mediates its effect via Nox4 inhibition in VSMC.
The role of Nox1 in Ang II signaling has been better characterized, suggesting ROS 
produced by Nox1 to be important for the EGF-R transactivation95, and also suggesting 
a clear dependence of Akt and p38 phosphorylation on Nox1 upon Ang II stimulation. In 
addition, data in HEK cells indicate a role of Nox1 in Ang II-induced ROS production234, 
and reports showed that Rac1 is needed for the stimulation of NADPH oxidase activity 
by Ang II181, 205. Other groups also showed, that the AT1R and Nox1 are co-localized in 
caveolae191, indicating an interaction during Ang II signaling. Using a Nox1 blocking 
peptide that inhibited the assembly of Nox1 and therefore its function, we found that 
Ang II-induced phosphorylation of Akt and p38 was inhibited signifi cantly. This underlines 
the importance of Nox1 in Ang  II signaling and shows a clear dependence of the Ang II 
signaling pathway on Nox1. In contrast, EGF-mediated phosphorylation of Akt and MAPK 
was not signifi cantly altered in cells with impaired Nox1-assembly. Another publication 
found Nox1 as a main source for Akt activation upon Ang II stimulation only in VSMC of 
spontaneously hypertensive rats, not in VSMC of control animals.149 A possible explanation 
might be that our cultivated VSMC display a phenotype differing from their smooth muscle 
cells. In addition a Nox1 regulation of Ang II signaling in VSMC was also found by other 
groups186 supporting our results. To sum up our results we exclude a redox-dependent 
mechanism downstream of the EGF-R but point out a pivotal role of Nox1 in the Ang II 
signaling, while no infl uence of Nox4 was found. Further, RV was not found to inhibit 
Nox1 or Nox4.
Application of AEBSF, a Nox inhibitor208, to the cells led to some reduction of ROS produced 
after Ang II stimulation, similar to data described in the literature212, 235, 236 whereas even an 
increase of Akt phosphorylation was detected in our cells. Therefore we concluded that 
Nox inhibition in VSMC by AEBSF in the concentrations tested (50 μM - 1 mM) was not 
potent enough to inhibit Akt phosphorylation, although the ROS level was decreased when 
pretreating the cells with 100 μM AEBSF.
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Downstream of the EGF-R, PI3K was suggested as a main player involved in ROS 
production in VSMC164. Transactivation and phosphorylation of the EGF-R after Ang II 
stimulation was already shown to be redox-sensitive, whereas no ROS is needed for a 
direct activation of the EGF-R with EGF.229 However, redox-dependent signaling steps 
downstream of the EGF-R were suggested in VSMC164. In agreement with these fi ndings 
we found an abrogation of Akt and p38 phosphorylation upon Ang II stimulation following 
pretreatment with DPI and NAC. Concerning ERK1/2 phosphorylation, we only detected 
an inhibition by NAC, confi rming experiments by Frank et al70, while other groups also 
reported an inhibition of Ang II-mediated ERK1/2 phosphorylation by DPI71. Reason 
for this discrepancy is unknown, although differences in cellular systems used might be 
one explanation. Interestingly, when stimulating cells with EGF, we could not detect any 
infl uence of DPI and NAC on Akt phosphorylation, suggesting that despite the extracellular 
ROS production after EGFR transactivation164 ROS are dispensable for this signaling step. 
In summary, our data indicate that the transactivation of the EGF-R by Ang II stimulation 
is ROS dependent, but we could not fi nd evidence for redox sensitive downstream signals 
of the EGF-R leading to Akt phosphorylation. Moreover, we found differences in the 
phosphorylation of MAP-kinases upon Ang II-stimulation when pretreating with DPI and 
NAC antioxidants compared to preincubation with RV. RV interferes specifi cally only with 
Akt phosphorylation, whereas DPI and NAC also diminished the phosphorylation of p38. 
In agreement with previous data of our group these fi ndings strongly indicate that also 
other than antioxidant properties of RV play a role in the inhibition of Akt-phosphorylation. 
Previous fi ndings showed that the transactivation of the EGF-R by Ang II was shown to 
be dependent on Noxes229, 237. RV, however, did not interfere with this transactivation, in 
contrast to NAC44. This is further supporting the assumption that RV is not mainly acting as 
antioxidant when interfering with Akt phosphorylation. 
By using additional antioxidants and redox-active compounds other than DPI, which is a 
rather unspecifi c fl avoprotein inhibitor, and NAC, a general antioxidant238, we wanted to 
further clarify the role of ROS in Ang II and EGF-mediated signaling in VSMC. In addition 
the hydroxyl radical scavengers DMTU and MPG were also tested concerning their effect 
on Akt phosphorylation. DMTU was shown to inhibit E-Hb-induced hydroxyl radicals in 
human aortic SMC239. In human VSMC also a reduction in intracellular hydroxyl radicals 
after oxLDL incubation was shown when applying 10 mM DMTU240 which proofed that 
DMTU is a hydroxyl radical scavengers in SMC. By preincubation of the cells with 50 μM - 
10 mM DMTU, no infl uence in Akt phosphorylation after Ang II stimulation was detectable. 
Differences between our results and the literature can be due to distinct experimental setups 
and cell types as both DMTU effects of other groups were found in human but not rat 
VSMC. An effectiveness of MPG was shown in vivo in myocardial ischemia-reperfusion 
(IR) injury models by infl uencing positively post ischemic myocardial dysfunction when 
– 87 –Discussion
acting as hydroxyl scavenger212 and preventing H2O2-induced left ventricle dysfunction
235. 
Also in TNF-α treated myoblasts MPG at a concentration of 10 μM was shown to inhibit 
ROS production241 and the ET-1-induced positive inotropic effect in rat myocytes was 
inhibited by 2 mM MPG. As MPG was shown to have antioxidative effects in various cell 
systems we tested 50 - 300 μM MPG on our cells and found that it did not signifi cantly 
infl uence Akt phosphorylation in the tested concentrations. As MPG preincubation in some 
experiments showed a slight inhibition of Akt phosphorylation, we cannot completely 
rule out an effect of MPG, but this would have to be investigated further with varying 
concentrations and preincubation times.
We next investigated, whether the SOD and catalase mimetics EUK 134 and MnIIITM 
in various concentrations could mimic the RV effect in our cells. EUK134 was shown to 
act in myocytes on LPS-induced ROS216 and decrease IL-β2 induced MMP-2 levels in 
endothelial cells242, MnIIITM was shown to similarly reduce IL-β2 induced MMP-2 levels 
in endothelial cells242. In our system, however, EUK34 and MnIIITM did not affect Akt-
phosphorylation after Ang II pretreatment. 
As none of the tested inhibitors was able to mimic the RV effect by inhibition of Akt 
phosphorylation, we concluded that RV is not mainly acting as hydroxyl radical scavenger 
or SOD or catalase mimetic and we also found that hydroxyl radicals are not important in 
the Ang II signaling. 
1.2. Structure-activity relationship of RV and its derivates concerning   
 Akt inhibition
To get a better understanding about the importance of the antioxidative properties of RV 
when interfering with Ang II and EGF stimulation, RV derivatives, that are methylated on 
one or more –OH groups (synthesized by the group of Prof. Erker) and therefore were shown 
to be non-antioxidative27-29, were applied to VSMC. The derivates R1 and TM-RV were not 
as potent in reducing H2O2 level as RV (experiment performed by Julia Gesslbauer, diploma 
student; data not shown). TM-RV, methylated at all hydroxyl groups, was not able to inhibit 
the phosphorylation of Akt, whereas the R1 derivate, also considerable less redox active 
because of the methylation on the 4´OH group27, could inhibit phosphorylation as potent 
as RV. This is in accordance with our previous fi ndings showing that the antioxidative 
property of RV is not important for the effect on Akt phosphorylation. It also indicates a 
pivotal role of the 3´and 5´ OH groups which are not methylated in this derivative for the 
RV-mediated inhibition of Akt phosphorylation.
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Studies suggest that methylation protects dietary fl avonoids and possibly also polyphenols 
from a rapid hepatic metabolism as the free hydroxyl groups of most polyphenols favour 
a very rapid conjugation by glucuronidation and sulfation243, 244. Thus methylation could 
increase metabolic stability and therefore the human oral bioavailability, which would be 
important when using RV for oral formulations.245 Still, our study showed that methylation 
of the hydroxyl groups can interfere with the biological effects of RV, and therefore 
consumers should act with caution when using a metabolically more stable but methylated 
derivative of RV.
2. Shp2 and RV action
2.1. Shp2 and ROS
A previous publication indicated that Shp2 can infl uence ERK1/2 and Akt signaling 
downstream of the EGF-R.220 By dephosphorylation of the PI3K binding site of Gab1 Shp2 
can inhibit the Akt phosphorylation in mouse fi broblasts.154 Also a direct activation of Shp2 
by RV was shown44, leading to the assumption that Shp2 is a direct target of RV in VSMC 
when interfering with Akt phosphorylation. One possible mode for the activation of Shp2 
by RV would be via keeping it in a reduced, active status by avoiding oxidation of Shp2 
due to Ang II- or EGF-triggered ROS production. During our study we found no increase 
in the oxidation of Shp2 upon Ang II or EGF stimulation, although such a modifi cation of 
Shp2 was shown in cardiac fi broblasts stimulated with Endothelin-1 (ET-1), that similarly 
utilizes signal transduction via the EGF-R .246 Interestingly, we found already oxidized 
Shp2 in unstimulated cells, which is in agreement with the high basal ROS levels detected 
in our cells. In the literature, contradictory data exists about the increase in Shp2-oxidation 
upon Ang II stimulation: A recent publication showed no oxidation of Shp2 after Ang II 
stimulation with an in-gel–assay, but could on the other hand measure an increase of oxidized 
Shp2 with an antibody-based assay, that was also used in this thesis.149 Additionally, another 
publication suggested that redox regulation of Shp2 strongly depends on the cell type and 
pointed out that the usage of antibodies against oxidized phosphatases in vitro might not be 
sensitive enough to detect intracellular phosphatases.148 Therefore, the interpretation of our 
data collected with this antibody-assay is diffi cult, and no conclusion on a redox regulation 
of Shp2 after Ang II stimulation could be drawn. Moreover, it was recently shown that the 
stably oxidized form of Shp2 consists of a backdoor-backdoor disulfi de bridge while the 
catalytic cysteine remains in a reduced state, which makes it problematic to detect oxidized 
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Shp2 with techniques based on trapping of sulphenic acids or modifi ed cysteins at the 
active site.135 
2.2. Shp2 phosphorylation in Ang II and EGF signaling
Similar to oxidization, phosphorylation of Shp2 is a posttranslational way of regulating 
Shp2 activity. As RV was shown to activate Shp2 activity44, it was interesting to investigate, 
whether this is achieved by phosphorylation. When testing phosphorylation of Shp2 
after Ang II or EGF stimulation we found a different pattern. Ang II induced a strong 
hyperphosphorylation of Shp2, whereas only a slight alteration was detectable after EGF 
treatment, confi rming data from the literature145, 149. Addition of RV had no signifi cant effect 
on Shp2 phosphorylation; only a slight increase of Ang II-mediated Shp2 phosphorylation 
could be seen. In contrast, Ang II was shown to reduce phosphorylation of Shp2 in endothelial 
cells156, indicating different effects in different cell types. Shp2 was further shown to attach 
to unstimulated AT1R, infl uencing Ang II-induced JNK/STAT signaling in fi broblasts247, 
which could be an explanation for the different effects of Ang II and EGF in our cells.
Antioxidant treatment of cells showed that NAC was not able to inhibit Ang II-induced 
phosphorylation of Shp2, indicating no dependence of Shp2-phosphorylation on ROS. This 
is not in agreement with a report providing evidence that ROS (originated from Nox1) is 
important for Shp2 phosphorylation.149 For a fi nal clarifi cation also the infl uence of Noxes 
on Shp2 phosphorylation has to be tested. But as RV is not causing the same effect on Shp2 
phosphorylation compared to antioxidants, it again excludes a major role of RV as redox-
active compound in the signaling in VSMC.
The role of Shp2 for signaling processes, however, is controversially discussed in the 
literature. Beside its regulatory role of enhancing ERK1/2 signaling220 and the inhibition of 
p85 binding to the EGF-R via Gab1154, other experiments using mouse embryonic fi broblast 
cells with a deletion at exon 3 (Shp2Ex3-/-) - a viable Shp2 knock out model - showed an 
infl uence of Shp2 on MAPK dependent on the stimulus. In that model PDGF led to a 
hyperphosphorylation of MAPK, while FGF was not able to induce an activation of MAPK 
when compared to wild-type cells.248 In VSMC, a different publication showed that Shp2 is 
activated and phosphorylated by Ang II and then inhibits MAPK activation by interfering 
with c-Src.249 Also a positive effect of Shp2 on Akt/PI3K after stimulation of fi broblasts 
with interleukin (IL)-3 is reported250, as well as an activation of Shp2 during IGF-1 induced 
Akt activation.251 In addition, in cancer cells, but also in Shp2 Ex3-/- fi broblasts, Shp2 was 
shown to activate Akt in dependence of EGF and PDGF.252 These publications lead to the 
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conclusion that Shp2 is a widely distributed phosphatase that can modulate MAPK and Akt 
activation differently, depending on the nature of the stimulus and the cell line used. Our 
data also indicate a different role of Shp2 in Ang II and EGF signaling. Therefore some 
general experiment concerning the role of Shp2 in the Ang II and EGF signaling in VSMC 
are needed to further defi ne Shp2-dependent mechanism in this cell type.
2.3. Shp2 and PI3K
We showed that Ang II stimulation increases Shp2 phosphorylation, whereas EGF treatment 
had no effect on Shp2 phosphorylation. In addition, we found a EGF-induced p85 (PI3K 
subunit) recruitment to Shp2 (as obvious in co-immunoprecipitation) but no interaction 
after Ang II stimulation. Combining our fi ndings on Shp2 phosphorylation with these data 
we suggest that Ang II stimulation leads to the phosphorylation and activation of Shp2 
which in turn dephosphorylates the binding site for PI3K and inhibits PI3K recruitment 
to the Shp2 containing “signaling complex”. After EGF stimulation, however, Shp2 is not 
phosphorylated signifi cantly and therefore PI3K can be recruited to Shp2, or the “signaling 
complex”, leading to a much stronger Akt signaling compared to the stimulation with 
Ang II. This hypothesis is supported by the data that Shp2 can dephosphorylate the binding 
site of p85 subunit of PI3K on Gab1.154 As RV did not seem to have any signifi cant impact 
on Shp2 phosphorylation, a regulation of Shp2 phosphorylation is not an explanation for 
RV action.
A possible reason for the differences in Ang II and EGF signaling was shown by studies 
in different cell lines including cancer cells, Vero and HEK cells, stating that the PI3K 
activity is only important for Gab1- and Shp2-mediated ERK1/2 activation upon weak EGF 
signaling. When signal strength increases, the cells rather act via Grb2-mediated binding 
of Gab1 and Shp2, independent of PI3K.253 Experiments in our cells with WM, a PI3K 
inhibitor, in combination with EGF and Ang II stimulation both showed a clear dependence 
of Akt phosphorylation on PI3K, whereas ERK1/2 was not infl uenced by this inhibition 
(data not shown). Our data suggest that for Akt activation in our cells, PI3K is important, 
albeit the specifi c regulation might differ between the two stimuli. Still, as clear PI3K 
activity data in the presence of RV are missing, a mechanism of RV targeting PI3K cannot 
be ruled out yet. 
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Finally, Shp2 knock down indicates a marginal role of Shp2 on the RV effect, as knock down 
of Shp2 by 50 % did not infl uence the Akt-phosphorylation and RV effect signifi cantly. 
However, because of the 50 % reduction, there still might remain enough Shp2 in the cells 
to mediate Akt phosphorylation and RV effect. Anyway we could not fi nd any mechanism 
how RV is activating Shp2 and therefore inhibiting Akt phosphorylation after Ang II or 
EGF activation.
3. Ang II and EGF signaling
The transactivation of EGF-R by Ang II is triggered by the Ang II-induced cleavage 
of HB-EGF, that binds to the EGF-R72, activating a signaling cascade downstream of 
the receptor. Using AG1478, an EGF-R kinase inhibitor, we found no difference in the 
Ang II-mediated Shp2 phosphorylation. Referring to these data we showed that of Shp2 
phosphorylation occurs upstream of the EGF-R, maybe via a regulation by the AT1R in 
VSMC. In addition, experiments with the EGF-R kinase inhibitor showed that only 50 % 
of the Akt phosphorylation in response to Ang II is regulated via the EGF-R. p38 activation 
seems to be controlled by the EGF-R at about 60 % and ERK1/2 phosphorylation at even 
70 % in our cell system. The latter result is in contrast to other groups, that showed that 
ERK1/2 stimulation by Ang II-mediated signaling is completely independent of EGF-R 
transactivation in HEK cells254 and also in preglomerular SMC255, but that it seems to be 
dependent on c-src activation in VSMC256. In contrast other groups showed a total dependence 
of ERK1/2 phosphorylation88 and Akt phosphorylation257 after Ang II stimulation in rat 
VSMC on the EGF-R. Our data indicated a difference in Ang II and EGF induced signaling 
concerning the regulation of these kinases. When taking into account the literature a strong 
dependence on the cell type, stimulus and experiment setting is likely. Therefore additional 
experiments to clarify the signaling of Ang II in contrast to EGF downstream of the EGF-R 
in our cell system are needed.
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4. Other possible mechanisms of RV
RV is a known activator of Sirtuins, linking it to increased life-span which led to its 
reputation as an anti-aging compound. We tested whether sirtuin plays a role for RV-
mediated inhibition of Akt phosphorylation by using sirtinol, a sirtuin inhibitor. Similar to 
data obtained in mesengial cells where a sirtuin-independent inhibition of Akt after PDGF 
stimulation was found258,we were not able to detected a dependence of the RV effect on 
sirtuins in our cells. Therefore we could rule out a role of Sirtuin as modulator of the Akt 
phosphorylation, and consequently as a RV target, in our cell system. 
RV is a phytoestrogen245 and was reported to selectively bind to αVβ3 integrins on the cell 
surface259. A strong dependence of the RV effect on α-estrogen receptor and integrins αVβ3 
in EGF- signaling was, however, excluded by our group. Other data showed that Shp2 
slightly reverses EGF-induced FAK phosphorylation, and that this effect was overcome 
by RV (Dissertation Mario Kumerz, Univ. of Vienna, 2009). Together with minor changes 
after RV pretreatment on Shp2 phosphorylation a synergistic effect of RV on several 
molecules including Shp2 and FAK can not be ruled out at this moment and warrants further 
investigations. 
In summary, we have investigated a possible mode of action of RV when inhibiting Ang II- 
or EGF-induced Akt phosphorylation after stimulation in VSMC. By acting as antioxidant 
RV was believed to inhibit Shp2 oxidation and therefore restore its activity leading to 
an inhibition of Akt phosphorylation. We could show that indeed RV is able to inhibit 
intra- and extracellular ROS in VSMC, but unexpectedly it did not act as antioxidant when 
inhibiting Akt phosphorylation. Further we identify Nox1 as major ROS source after Ang II 
but not EGF stimulation and therefore showed evidence that the signaling downstream of 
the EGF-R seems to be redox independent. In addition we rule out a role for Nox4 in these 
signaling pathways. We could not fi nd any mechanism of RV-mediated Shp2 activation, but 
we detected differences in the phosphorylation of Shp2 and in PI3K recruitment to Shp2 
upon stimulation of cells with Ang II or EGF. This work shows that RV is not just acting as 
an antioxidant in cells but that it has a more specifi c mode of action and therefore additional 
studies are needed to identify this very potent and selective effect of RV in VSMC.
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1. Abbreviations
A
AEBSF  4-(2-Aminoethyl)-benzenesulfonyl Fluoride
Ang II   Angiotensin II
ANOVA  Analysis of variance between groups
Akt   Protein kinase B
APS   Ammonium persulphate
AT1R   Angiotensin receptor 1
B
BSA   Bovine serum albumin
C
cDNA   Complementary DNA 
CS   Calf serum
D
DCF   2´,7´-dichlorofl uorescein
DMEM  Dulbecco’s modifi ed Eagle’s medium 
DMSO   Dimethyl sulfoxide
DMTU  Dimethyl thiourea
DNA   Desoxyribonucleic acid
dNTP   Deoxyribonucleotide triphosphate 
ddH2O   Double distilled water
DPI   Diphenyleneiodonium
DTT   Dithiothreitol
E
EC   Endothelial cells
ECL   Enhanced chemiluminescence
EDTA   Ethylenediamintetraacetic acid
EGF   Epidermal growth factor
EGF-R   Epidermal growth factor receptor
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ERK   Extracellular signal-regulated kinase
F
FACS   Fluorescence-activated cell sorter
FITC   Fluorescein isothiocyanate
FOXO   Forkhead box-O transcription factors
G
Gab   Grb-2associated binder (Gab)
GAP   GTPase activating protein
Grb   Growth factor receptor binding protein 
GSK   Glycogen synthase kinase 3
GTP   Guanosine triphosphate
H
HBSS   Hank’s balanced salt solution
H2DCF  2´,7´-dichlorodihydrofl uorescein 
H2DCF-DA  2´,7´-dichlorodihydrofl uorescein-diacetate
HDAC   Histone deacetylase
HEPES  N-(2-hydroxyethyl)piperazine-N´-(2-ethanesulphonic acid)
I
IAA   Iodoacetic acid
IP   Immunoprecipitation
J
JNK   c-Jun N-terminal kinase
K
kDA   kilo Dalton
L
LDL   Low density lipoprotein
LMW-PTP  Low molecular weight protein-tyrosine phosphatase
M
MAPK   Mitogen activated protein kinase
Mc   Monoclonal
MnIIITM   Mn(III)terakis(1- methyl-4-pyridyl) porphyrin pentachloride 
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MPG   N-(2-mercaptopropionyl)-glycine
mRNA   Messenger RNA
N
NAC   N-acetyl-cysteine
NADPH  Nicotinamide adenine dinucleotide phosphate
NF- κB  Nuclear factor- κB
Nox   NADPH-oxidase
P
PAA   Polyacrylamide
PBS   Phosphate buffered saline
Pc   Polyclonal
PCR   Polymerase chain reaction
PDK1/2  Phosphoinositide-dependent protein kinase 1/2
PH domain  Pleckstrin homology domain
PI3K   Phosphatidylinositol 3-kinase
PIP2   Phophatidylinositol-4,5-bisphosphate
PIP3   Phophatidylinositol-3,4,5-trisphosphate
PKA   Protein kinase A
PKC   Protein kinase C
PKG   Protein kinase G
PMSF   Phenylmethylsulphonylfl uoride
PTEN   Phosphatase and tensin homologue deleted on chromosome ten
PTP   Protein tyrosine phosphatase
PVDF   Polyvinylidenedifl uoride
Q
qPCR   Quantitative real-time PCR
R
RNA   Ribonucleic acid
RNAi   RNA interference
ROS   Reactive oxygen species
RT   Reverse transcription
RTK   Receptor tyrosine kinase
RT-PCR  Real time PCR
RV   Resveratrol
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S
SDS   Sodium dodecyl sulphate
SDS-PAGE  Sodim dodecyl sulphate polyacrylamide gel electrophoresis
SEM   Standard error of the mean
Ser   Serine
SH2 domain  Src-homology 2 domain
SHIP   SH2-containing inositol 5-phosphatase
Shp2   SH2 domain-containing phosphatase 2
SIRT1   Sirtuin 1
SOD   Superoxide dismutase
SOS   Son of sevenless
T 
TBS-T   Tris-buffered saline containing Tween 20
T/E   Trypsin/EDTA solution
TEMED  N,N,N´,N´-tetramethylethylene diamine+
Thr   Threonine
Tyr   Tyrosin
U
U   Units
V
VSMC   Vascular smooth muscle cells
W
WM   Wortmannin
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4. Short lecture
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